0001607062-21-000341.txt : 20210924 0001607062-21-000341.hdr.sgml : 20210924 20210924075431 ACCESSION NUMBER: 0001607062-21-000341 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210924 DATE AS OF CHANGE: 20210924 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SYBLEU Inc CENTRAL INDEX KEY: 0001818674 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851412307 STATE OF INCORPORATION: WY FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-248059 FILM NUMBER: 211274068 BUSINESS ADDRESS: STREET 1: 109 EAST 17TH STREET SUITE 460 CITY: CHEYENNE STATE: WY ZIP: 82001 BUSINESS PHONE: 6192279192 MAIL ADDRESS: STREET 1: 109 EAST 17TH STREET SUITE 460 CITY: CHEYENNE STATE: WY ZIP: 82001 10-K 1 sybleu063021form10k.htm 10-K
0001818674 false 06/30 2021 FY 0001818674 2020-07-01 2021-06-30 0001818674 2021-09-20 0001818674 2021-06-30 0001818674 2020-06-30 0001818674 2020-06-13 2020-06-30 0001818674 us-gaap:CommonStockMember 2020-06-30 0001818674 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001818674 us-gaap:RetainedEarningsMember 2020-06-30 0001818674 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001818674 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001818674 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001818674 2020-07-01 2020-09-30 0001818674 us-gaap:CommonStockMember 2020-09-30 0001818674 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001818674 us-gaap:RetainedEarningsMember 2020-09-30 0001818674 2020-09-30 0001818674 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001818674 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001818674 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001818674 2020-10-01 2020-12-31 0001818674 us-gaap:CommonStockMember 2020-12-31 0001818674 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001818674 us-gaap:RetainedEarningsMember 2020-12-31 0001818674 2020-12-31 0001818674 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001818674 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001818674 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001818674 2021-01-01 2021-03-31 0001818674 us-gaap:CommonStockMember 2021-03-31 0001818674 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001818674 us-gaap:RetainedEarningsMember 2021-03-31 0001818674 2021-03-31 0001818674 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001818674 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001818674 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001818674 2021-04-01 2021-06-30 0001818674 us-gaap:CommonStockMember 2021-06-30 0001818674 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001818674 us-gaap:RetainedEarningsMember 2021-06-30 0001818674 us-gaap:CommonStockMember 2020-06-12 0001818674 us-gaap:AdditionalPaidInCapitalMember 2020-06-12 0001818674 us-gaap:RetainedEarningsMember 2020-06-12 0001818674 2020-06-12 0001818674 us-gaap:CommonStockMember 2020-06-13 2020-06-30 0001818674 us-gaap:AdditionalPaidInCapitalMember 2020-06-13 2020-06-30 0001818674 us-gaap:RetainedEarningsMember 2020-06-13 2020-06-30 0001818674 2021-07-08 0001818674 CIK0001818674:StephenHakeMember 2020-11-01 2020-11-05 0001818674 CIK0001818674:DavidRKoosMember 2020-07-01 2021-06-30 0001818674 CIK0001818674:BSTPartnersMember 2020-07-01 2021-06-30 0001818674 CIK0001818674:DavidRKoosMember 2021-06-30 0001818674 CIK0001818674:BSTPartnersMember 2021-06-30 0001818674 CIK0001818674:OncologyPharmaIncMember 2021-03-01 2021-03-11 0001818674 CIK0001818674:OncologyPharmaIncMember 2020-07-01 2021-06-30 0001818674 CIK0001818674:OncologyPharmaIncMember 2021-06-30 0001818674 CIK0001818674:DrStephenHakeMember 2020-07-01 2020-07-08 0001818674 CIK0001818674:DrJasonGarberMember 2020-07-01 2020-07-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

United States Securities and Exchange Commission

Washington, D.C.  20549

Form 10-K

☒  ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934:

For the fiscal year ending June 30, 2021

☐  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934:

For the transition period from __________ to __________. 

Commission file number: 333-248059 

SYBLEU INC.
(Name of small business issuer in its charter)
     
Wyoming   85-1412307
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)
     
4700 Spring Street, Suite 304, La Mesa, California, 91942
(Address of Principal executive offices)

Issuer’s telephone number: (619) 227-9192 

Securities registered under Section 12(b) of the “Exchange Act”: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☐  No ☒  

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or smaller reporting company.

Large accelerated filer ☐ Accelerated filer  ☐
Non-accelerated Filer ☐ Smaller reporting Company  ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes ☐  No ☒  

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☐ No ☒  

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter:   N/A 

As of September 20, 2021 SYBLEU INC had : 10,418,000 common shares outstanding. 

1 
 


In this annual report, the terms “SYBLEU INC.. ”, “SYBLEU”, “Company”, “we”, or “our”, unless the context otherwise requires, mean SYBLEU INC., a Wyoming corporation..

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This annual report on Form 10-K and other reports that we file with the SEC contain statements that are considered forward-looking statements.  Forward-looking statements give the Company’s current expectations, plans, objectives, assumptions or forecasts of future events. All statements other than statements of current or historical fact contained in this annual report, including statements regarding the Company’s future financial position, business strategy, budgets, projected costs and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “plans,” “potential,” “projects,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend,” and similar expressions. These statements are based on the Company’s current plans and are subject to risks and uncertainties, and as such the Company’s actual future activities and results of operations may be materially different from those set forth in the forward looking statements. Any or all of the forward-looking statements in this annual report may turn out to be inaccurate and as such, you should not place undue reliance on these forward-looking statements.  The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. The forward-looking statements can be affected by inaccurate assumptions or by known or unknown risks, uncertainties and assumptions due to a number of factors, including:

•   dependence on key personnel;

 

•   competitive factors;

 

•   degree of success of research and development programs

 

•   the operation of our business; and

 

•   general economic conditions

 

These forward-looking statements speak only as of the date on which they are made, and except to the extent required by federal securities laws, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements contained in this annual report.

2 
 

PART I

Item 1. Business

We were incorporated June 12, 2020 under the laws of the State of Wyoming. We are a majority owned subsidiary of Cell Source Research, Inc., a Delaware corporation. We intend to engage primarily in the development of regenerative medical applications up to the point of successful completion of Phase I and or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The primary factor to be considered by us in arriving at a decision to advance an application further to Phase III clinical trials would be a greater than anticipated indication of efficacy seen in Phase I trials.

On July 14, 2020 we were assigned all right, title, and interest to intellectual property related to methods, devices, and techniques useful for enhancing function of a cellular graft through photoceutical ( the use of low level light therapeutics) manipulation. These rights were assigned to us by the Company’s Chief Executive Officer and Entest Biomedical, Inc., a California corporation controlled by the Company’s Chief Executive Officer.

This intellectual property forms the basis of the Company’s first medical application under development ( “Cell Transplant IP”).

Principal Products and Services

 

The Cell Transplant IP comprises methods, devices, and techniques useful for enhancing function of a cellular graft through photoceutical manipulation.

The Cell Transplant IP encompasses the following:

  (a) Methods of increasing efficacy of a cell for use in transplantation by pretreatment of said cell prior to transplantation with a laser irradiation

 

  (b) Methods of augmenting efficacy of a cellular graft subsequent to transplantation by treating the area in which said graft will be transplanted with laser irradiation

 

  (c) Methods of decreasing neutropenic (Neutropenia is a condition that results when the body does not have enough neutrophils, an important white blood cell that fights infections) time in a patient subsequent to a hematopoietic cell transplantation consisting of: a) extraction of a hematopoietic ( blood cell forming) stem cell source; b) administration of low level laser irradiation to said hematopoietic stem cell source at a sufficient energy and wavelength to increase hematopoietic reconstitution activity of said hematopoietic stem cell source; c) administration of treated cells; and/or d) providing low level laser irradiation to long bones of said patient at a sufficient energy and wavelength to increase hematopoietic stem cell engraftment.

 

  (d) Methods of treating a cytopenia ( low blood cell count) consisting of : a) extraction of a hematopoietic stem cell source; b) administration of low level laser irradiation to said hematopoietic stem cell source at a sufficient energy and wavelength to increase hematopoietic reconstitution activity of said hematopoietic stem cell source; c) administration of treated cells; and/or d) providing low level laser irradiation to long bones of said patient at a sufficient energy and wavelength to increase hematopoietic stem cell engraftment.

 

The Cell Transplant IP is intended to be utilized primarily in connection with Hematopoietic stem cell transplantation. Hematopoietic stem cell transplantation involves the intravenous infusion of autologous or allogeneic stem cells collected from bone marrow, peripheral blood, or umbilical cord blood to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective.

In hematopoietic cell transplantation, the patient is given very high doses of chemotherapy or radiation therapy, intended to kill resistant cancer cells. This also destroys the normal cells in the bone marrow, including stem cells. After the treatment, the patient is given a supply of transplanted stem cells. The transplanted cells then reestablish the blood cell production process in the bone marrow.

3 
 

 

In situations of hematopoietic stem cell transplantation recipient bone marrow is usually ablated in order to provide “space” for the donor bone marrow cells. Additionally, when treatment of hematological malignancies is being performed, the recipient cells need to be eradicated in order to cure the neoplasia (uncontrolled growth of cells). This process of hematological ablation (removal of tissue) involves exposing the patient to a period of immune deficiency. During this period multiple infections occur, which in a non- insignificant number of cases are lethal. Accordingly, it is of great interest accelerate the process of donor bone marrow engraftment and hematopoietic reconstitution.

The Cell Transplant IP provides means of “preactivating” a cellular graft before implantation. Said “preactivation” refers to induction of biochemical processes within the graft so as to allow for: a) increased viability; b) augmented function; c) accelerated integration with the tissue in which implantation of cellular graft has occurred. In the context of hematopoietic stem cell the IP provides methods of augmenting ability of transplanted stem cells to enter and incorporate into the bone marrow niche, to self renew and proliferate once established in said niche, and to generate blood cells. Preactivation is accomplished through the use of low level laser irradiation before infusion. Administration of low level laser irradiation to long bones may also be used for acceleration of stem cell reconstitution after administration. The above statements regarding preactivation of a cellular graft and any descriptions within this document of the benefits of preactivating a cellular graft with the Cell Transplant IP before implantation are based solely on management’s belief.

The preactivation of stem cells before administration in myeloablated patients may be performed with a medical device comprised of a closed system. Myeloablation is a severe form of myelosuppression; a condition in which bone marrow activity is decreased, resulting in fewer red blood cells, white blood cells, and platelets.

Said device contains an inlet that connects in a closed manner to a cryobag using connection systems available in the art such as Leuer Lock (a device utilizing leak free fittings which are securely joined by means of a tabbed hub on the female fitting which screws into threads in a sleeve on the male fitting). Access to cells pre and post-irradiation is provided using valves that allow for sample collection. This is an important part of quality control for the cells. Classical parameters of interest include cell viability and morphology.

Said device further consists of a surface area of sufficient size so that cells from the cryobag or other sterile source can be exposed to irradiation in a uniform or semi-uniform manner. Said device may further possess a rocking mechanism to ensure cell dispersion. Under the surface area a low level laser is provided that administers the desired frequency and intensity of laser irradiation to said cells

The Company has yet to either develop or in license the closed system described above. Such a closed system would likely be regulated as a Medical Device. The FDA regulates the development, clinical testing, manufacturing, labeling, storage, record-keeping, promotion, marketing, sales, distribution and post-market support and reporting of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses.

Unless an exemption applies, before a medical device can be commercially distributed in the United States and, depending on the classification of the device, either prior 510(k) clearance, 510(k) de-novo clearance or premarket approval (PMA), must be obtained from the FDA. A 510(k) is a premarket submission made to FDA to demonstrate that the device to be marketed is as safe and effective, that is, substantially equivalent, to a legally marketed device. A 51(k) de novo establishes new “device type” along with classification)

The FDA classifies medical devices into one of three classes based on the degree of risk associated with each medical device and the extent of regulatory controls needed to ensure the device’s safety and effectiveness:

•   Class I devices, which are low risk and subject to only general controls (e.g., registration and listing, medical device labeling compliance, Medical Device Reporting Regulations, Quality System Regulations, and prohibitions against adulteration and misbranding) and, in some cases, to the 510(k) premarket clearance requirements;

 

•   Class II devices, which are moderate risk and generally require 510(k) or 510(k) de-novo premarket clearance before they may be commercially marketed in the United States as well as general controls and potentially special controls like performance standards or specific labeling requirements; and

 

•   Class III devices, which are devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a predicate device. Class III devices generally require the submission and approval of a PMA supported by clinical trial data.


 

4 
 

 

No assurance can be given that any device which may be utilized to function as part of the “closed system” described would be granted approval by the FDA to be commercially distributed. The Company has yet to determine whether it will attempt to develop such a “closed system” internally or attempt to in license such a system. Such determination is intended to occur upon consultation with a Contract Research Organization or other qualified expert. The Company has yet to retain a Contract Research Organization or consult with an expert qualified to advise the Company regarding medical devices. The Company has not conducted any preclinical studies to provide evidence of the Company’s belief that the Cell Transplant IP provides a means to preactivate a cellular graft before implantation and that such preactivation would provide the benefits described above.

In arriving at the belief that the Cell Transplant IP provides a means to preactivate a cellular graft and that such preactivation would provide the benefits described above the Company took into consideration the following published studies :

“Low Level Laser Irradiation Precondition to Create Friendly Milieu of Infarcted Myocardium and Enhance Early Survival of Transplanted Bone Marrow Cells” Published in the Journal of Cellular and Molecular Medicine September 2009.

Study addressed: (1) whether low-level laser irradiation (LLLI) pre-treatment change the local cardiac micro-environment after myocardial infarction (MI) and (2) whether the LLLI preconditions enhance early cell survival and thus improve therapeutic angiogenesis and heart function. This study demonstrated that LLLI precondition significantly enhanced early cell survival rate of implanted bone marrow mesenchymal stem cells ( BMSCs) by 2-fold and decreased the apoptotic (cell self-destruction ) percentage of implanted BMSCs in infarcted myocardium and thus increased the number of newly formed capillaries. Mesenchymal stem cells (MSCs) are multipotent stem cells found in bone marrow that are important for making and repairing skeletal tissues, such as cartilage, bone and the fat found in bone marrow.

“In vitro effects of low-level laser irradiation for bone marrow mesenchymal stem cells: proliferation, growth factors secretion and myogenic differentiation.” Published December 2008 in Lasers in Surgery and Medicine..

This study concluded that LLLI stimulates proliferation, increases growth factors secretion and facilitates myogenic differentiation of BMSCs. Therefore, LLLI may provide a novel approach for the preconditioning of BMSCs in vitro prior to transplantation.

“Low-level laser irradiation (LLLI) promotes proliferation of mesenchymal and cardiac stem cells in culture” published in Lasers in Surgery and Medicine April 2007.

Isolation of MSCs and CSCs was performed. The cells were cultured and laser irradiation was applied. The number of MSCs and CSCs up to 2 and 4 weeks respectively, post-LLLI demonstrated a significant increase in the laser-treated cultures as compared to the control. This study demonstrates the ability of LLLI to promote proliferation of MSCs and cardiac stem cells (CSCs) in vitro.

All of the abovementioned studies were conducted by third parties unaffiliated with the Company or management of the Company.

On December 2, 2020 SYBLEU INC. (the “Company”) was assigned all right, title, and interest to intellectual property related to intratumoral administration of a combination of a chemotherapeutic agent and an immunomodulatory agent for cancer therapy ( “Cancer Therapy IP”).


The concept of the Cancer Therapy IP is the simultaneous intratumoral injection of a chemotherapeutic agents in combination with immunomodulatory agents in sustained release formulations. The chemotherapeutic agent is for the purpose of directly killing the tumor cells for the release of antigens while the immunomodulatory protein or factor is to stimulate the antigenic response of the host to the antigens.

5 
 

These rights were assigned to the Company by the Company’s Chief Executive Officer and Entest BioMedical, Inc., a California corporation controlled by the Company’s Chief Executive Officer. The aforementioned assignment constituted a contribution of intellectual property to the Company. There is no termination date of the assignment. No term or condition of the assignment would cause ownership of the intellectual property rights to revert back to David Koos and Entest BioMedical, Inc. No payment of any sort is required by to be made the Company to either David Koos or Entest BioMedical, Inc. pursuant to the assignment. The Company is not required to meet any particular benchmark or pay a royalty of any sort pursuant to this assignment.

On February 24, 2021 SYBLEU INC. ( the “Company”) and Oncology Pharma, Inc. ( “Licensee”) entered into an agreement whereby the Company granted the Licensee an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by the Company (“Agreement”).

 

This intellectual property relates to intratumoral administration of a combination of a chemotherapeutic agent and an immunomodulatory agent for cancer therapy ( “Cancer Therapy IP”). The concept of the Cancer Therapy IP is the simultaneous intratumoral injection of a chemotherapeutic agents in combination with immunomodulatory agents in sustained release formulations. The chemotherapeutic agent is for the purpose of directly killing the tumor cells for the release of antigens while the immunomodulatory protein or factor is to stimulate the antigenic response of the host to the antigens.

 

The term of the Agreement is fifteen years from the Effective Date.

 

Pursuant to the Agreement:

 

  (a) Licensee shall pay to the Company a non-refundable, upfront payment of six thousand five hundred shares of Oncology Pharma, Inc. common stock as a license initiation fee which must be paid within 10 days of the Effective Date of the Agreement

 

  (b) royalties equal to five percent (5%) of the Net Sales of any Licensed Products in a quarter.

 

Net Sales are defined in the Agreement as the gross invoiced amount, and/or the monetary equivalent of any other consideration actually received by Licensee and/or its sublicensees, for the transfer of a Licensed Product, less any of the following items that are itemized on the relevant invoice or which Licensee can demonstrate have been actually paid or credited with respect to such transfer.

 

Licensed Product is defined in the Agreement as (a) any method, procedure, service or process that incorporates, uses, used, is covered by, infringes or would infringe any of the licensed intellectual property in the U.S. or foreign jurisdictions; and (b) any apparatus, material, equipment, machine or other product that incorporates, uses, used, is covered by, infringes or would infringe any of the licensed intellectual property in the U.S. or foreign jurisdictions but for the rights granted pursuant to this Agreement.

 

Oncology Pharma Inc. is a publicly traded company whose common shares trade on the OTC Pink market under the symbol ONPH.

 

Distribution methods of the products or services:

If circumstances allow and subject to then current market conditions and available capital, we intend to enter into licensing and/or sublicensing agreements with outside entities in order that the Company may, if the Company is successful in securing its intellectual property claims, allow it to obtain royalty income on the products and services which it may develop and commercialize.

6 
 

Competitive business conditions and the Company’s competitive position in the industry and methods of competition

We are recently formed and have yet to achieve consistent revenues or profits and there can be no assurance that we will generate revenues or, if are successful, that we can do so at levels that will allow us to achieve and sustain positive cash flow and profitability and, if so, for any period of time..  The industry in which we intend to compete are highly competitive and characterized by rapid technological advancement. Many of our competitors have greater resources than we do.

 

We intend to be competitive by utilizing the services and advice of individuals that we believe have expertise in their field in order that we can concentrate our resources on projects in which products and services in which we have the greatest potential to secure a competitive advantage  may be developed and commercialized .

 

To that effect, we have entered into nonemployee consulting agreements with individuals who we believe have a high level of expertise in their professional fields and who have agreed to provide counsel and assistance to us in (a) determining the viability of proposed projects (b) obtaining financing for projects and (c) obtaining the resources required to initiate and complete a project in the most cost effective and rapid manner.

 

These individuals are as follows:

 

SCIENTIFIC ADVISORY BOARD MENBERS

 

Dr. Steven E. Hake, M.D.

 

Dr. Hake obtained his medical degree from The Chicago Medical School. Dr. Hake has been certified by American Board of Radiology since June 1992. Dr. Hake’s professional affiliations are with the Alpha Omega Alpha Honorary Medical Society and the American College of Radiology.

On July 7, 2020 the Company entered into an agreement with Dr. Stephen Hake whereby Dr. Hake agreed to serve as a member of the Company’s Scientific Advisory Board. Pursuant to the Agreement the Company is obligated to issue to Dr. Hake 40,000 of the Company’s common shares within 20 days of the execution of the Agreement.

 

Pursuant to the Agreement Dr. Hake shall advise the Company on various matters regarding biotechnology for the Company. Dr. Hake Member shall refer Company to appropriate researchers on specific topics and provide input on research data the company is developing. The frequency and timing of such services shall be established on a mutually agreeable basis. In the event Dr. Hake is requested to provide research services, such services will be negotiated separately between Dr. Hake and the Company.

 

The Term of the Agreement commenced on July 8, 2020 and the Agreement shall expire on July 7,2021. The Term of the Agreement may be extended by mutual agreement between the parties.

 

40,000 common shares of SYBLEU INC. were issued to Dr. Hake on July 8, 2020 as consideration for his service as a member of the Company’s Scientific Advisory Board.

 

Dr. Jason E. Garber, MD.

 

Dr. Garber obtained his medical degree from The University of Texas Health Science Center at San Antonio. Dr. Garber is Board Certified in Neurological Surgery by the American Board of Neurological Surgery

Dr. Garber was awarded a Cloward Fellowship Award in 2001 and has authored the following papers in the following publications:

 

Hassenbusch, SJ, Garber, JE: “Alternative Intrathecal Agents for Pain,” Neuromodulation, Volume 2, Number 2, 1999 89-95.

Garber, JE, Hassenbusch, SJ: “Innovative Intrathecal Analgesics,” Pain surgery, Burchiel, K (ed): In Press.

Garber, JE, Hassenbusch, SJ: “Interventional Pain Management: Can Charges be Effectively Minimized without Compromising Quality?” Pain Digest: In Press.

Garber, JE, Hassenbusch, SJ: Neurosurgical Operations on the Spinal Cord. Bonica’s Management of Pain, 3rd Edition, Loeser, JD (ed), Medica, PA: Williams and Wilkins, 1998: In Press.

7 
 

 

Garber, JE, Hassenbusch, SJ: “Spinal Administration of Non-Opiate Analgesics in the Management of Pain,” Interventional Pain Management, 2nd Edition, Waldman, SD (ed), WB Saunders: In Press

Nguyen H, Garber JE, Hassenbusch SJ: Spinal Analgesics. In: Staats P and Fleisher LA (eds). Anesthesiology Clinics of North America, Saunders: Philadelphia, pp. 805-816, 2003.

Garber, JE, Thalgott JS, Christensen SD: Anterior Lumbar Interbody Fusion via the Anterior Retroperitoneal Approach: Strategic Tactics for Avoiding Complications. The NNI Journal, Volume 2, Issue 3, 2006 62-65.

Garber, JE, Thalgott JS, Fogarty M, Caiazza S: Dynamic Stabilization of the Lumbar Spine: Past, Present, and Future Innovations. The NNI Journal, Volume 3, Issue 1, 2007 pp. 84-87.

Garber, JE, Saxena RC, Malone K: The Identification and Treatment of a Lumbar Plasmacytoma: A Case Report and Topic Review. The NNI Journal, Volume 3, Issue 3, 2007 pp. 135-139

Garber, JE, Malone K: Utilizing a Lateral Extracavitary Approach for Failed Lumbar Spine Fusion Procedures: A Case Study with Imaging Considerations in Lumbar Fusions. The NNI Journal, Volume 4, Issue pp. 14-15.

Garber, JE, Christian G, Serrano S, Malone K: Surgical Treatment of Intradural Extramedullary Spine Tumors. The NNI Journal, Volume 5, Issue 1, April 2009.

 

Garber, JE, Christian G, Serrano S, Malone, K: Nail-Gun Misfire Resulting in Penetrating Intracranial Injury. The NNI Journal, Volume 5, Issue 1, April 2009.

 

Garber, JE, Christian G, Serrano S, Malone, K: Craniocervical Fixation Series and Review of Literature. The NNI Journal, Volume 6, Issue 1, Jan 2010.


 

Dr. Garber has made the following professional presentations:

 

1. 1999 Congress of Neurological Surgeons (CNS) Meeting, Boston, MA. Oral Presentation, Section on Pain II: Interventional Pain Management: Can Charges Be Effectively Minimized Without Compromising Quality?

 

2. 2000 Neurosurgery + Science + Management Symposium, New Orleans, LA. Oral Presentation: Cancer and Non-cancerous Pain Management.

 

3. 2001 Congress of Neurological Surgeons (CNS) Meeting, San Diego, CA. Poster Presentation: Extralaminar Posterior Cervical Dorsal Ramisectomy: A Modified Surgical Approach for the Treatment of Cervical Dystonia (Spasmodic Torticollis).

 

4. 2005 Medical Education Resources Making Sense of Spine Surgery Seminar, Las Vegas, NV. Oral Presentation: Spinal Disorders: Cervical Conditions and Treatment. Demonstration: Cervical Construct Demonstration: Atlantis Vision Cervical Plate.

 

5. Minimally Invasive Spinal Surgery. Sunrise Hospital and Medical Center Grand Rounds, June 1, 2005.

 

6. Oral Presentation: One Neurosurgeon’s Experience with STALIF, Newport Beach, CA, November 2007.

 

7. EuroSpine: What is the Role of Mystique plating and Bioresorbable Technology in anterior cervical Fusion Procedures? Bressels, Belgium, 2007.

 

8. Oral Presentation: Novel Minimally Invasive Spine Techniques, Las Vegas, NV, January 2008.

 

9. International Meeting on Advanced Spine Techniques, Hong Kong, China, July 2008. Poster Presentation: A Comparison of the Surgical Efficacy of ALIF and XLIF® L4-5 Fusion Procedures with Posterior Fixation.

 

8 
 

 

10. Congress of Neurological Surgeon’s 2008 Annual Meeting, Orlando, FL, September 2008. Poster Presentation: A Comparison of the Surgical Efficacy of ALIF and XLIF® L4-5 Fusion Procedures with Posterior Fixation.

 

11. North American Neuromodulation Society (NANS) 13th Annual Meeting, Las Vegas, NV, December 3-6 2009. Paper Presentation: Selective Dermatome Activation, Using a Novel Five-Column Spinal Cord Stimulation Paddle Lead: A Case Series.

 

12. International Society for the Advancement of Spine Surgery – 2 nd Asia Pacific Conference (2010 APSAS), Sanya, China, January 14-17 2010. Paper Presentation: Direct Lateral Approach Corpectomy for Severe Kyphotic Deformity Correction.

 

13. The Role of Permanent Vascular Protection in Anterior Spine Instrumentation – 39th Annual Symposium, Orlando FL. March 16-19, 2011. A Review of Ten Same Lumbar Level Reoperations, Society of Clinical Vascular Surgery.

 

14. International Society for the Advancement of Spine Surgery – Annual Meeting (SAS, 2011), Las Vegas. Poster Presentation: A Multi-center Retrospective Evaluation of a Cervical Integrated Interbody System.

 

15. Conejo Valley Journal Club, Sherman Oaks, CA. January, 2015. Oral Presentation: Benefits of an Integrated Interbody Device over Spacers and Plates.

 

16. Society for Minimally Invasive Spine Surgery Global Forum ’15 – Las Vegas, NV. November 6, 2015. Minimally Invasive Stabilization: A 5 year Level 1 Study of Spinal Stenosis Disease Management.

 

17. International Society for the Advancement of Spine Surgery, Metro Toronto, Canada, April 11-13, 2018. Clinical Experience of Integrated Interbody Fusion in Multi-level Cervical Fusion.

 

18. Society for Minimally Invasive Spine Surgeons Annual Forum ’18, Las Vegas Nevada. Multi-level Cervical Constructs in Clinical Practice using Integrated Interbody Fusion.

 

19. Society for Minimally Invasive Spine Surgeons Annual Forum ’18, Las Vegas Nevada. Interspinous Decompression Devices – Do They Have a Role?

 

20. Congress of Neurological Surgery’s 2018 annual meeting, Houston Texas, October 6-10, 2018. Integrated Interbody Fusion in Multi-level Cervical Constructs in Clinical Practice.

 

21. Congress of Neurological Surgery’s 2018 annual meeting, Houston Texas, October 6-10, 2018. Swan Neck Deformity Correction with Multilevel Anterior Cervical Integrated Cages.

 

22. International Spinal Deformity Symposium 4th Annual, November/December 2018. Multilevel Cervical Constructs in Clinical Practice using Integrated Interbody Fusion.

 

23. International Society for the Advancement of Spine Surgery, Anaheim, California, April 3, 2019. Oral poster presentation: Cervical spinal deformity correction utilizing an integrated interbody fusion devices from a single anterior approach.

 

24. North American Spine Society 34th annual meeting, Chicago, Illinois, September 25-28, 2019. Poster presentation: Integrated Interbody Fusion in Multilevel Cervical Constructs in Clinical Practice.

 

25. American College of Surgeons, San Francisco, California, October 28, 2019. Oral presentation: Integrated Interbody Fusion in Multi-level Cervical Constructs in Clinical Prectice.


 

Dr. Garber is affiliated with the Las Vegas Neurosurgical Institute in Las Vegas, Nevada.

 

9 
 

 

On July 7, 2020 the Company entered into an agreement with Dr. Stephen Garber whereby Dr. Garber agreed to serve as a member of the Company’s Scientific Advisory Board. Pursuant to the Agreement the Company is obligated to issue to Dr. Garber 25,000 of the Company’s common shares within 20 days of the execution of the Agreement.

 

Pursuant to the Agreement Dr. Garber shall advise the Company on various matters regarding biotechnology for the Company. Dr. Garber Member shall refer Company to appropriate researchers on a specific topics and provide input on research data the company is developing. The frequency and timing of such services shall be established on a mutually agreeable basis. In the event Dr. Garber is requested to provide research services, such services will be negotiated separately between Dr. Garber and the Company.

 

The Term of the Agreement commenced on July 8, 2020 and the Agreement shall expire on July 7,2021. The Term of the Agreement may be extended by mutual agreement between the parties.

 

25,000 common shares of SYBLEU INC. were issued to Dr. Garber on July 8, 2020 as consideration for his service as a member of the Company’s Scientific Advisory Board.

 

The Company is currently continuing to search for other experts to serve on the Company’s Scientific Advisory Board.

 

Sources and availability of raw materials and the names of principal suppliers

The supplies and materials required to conduct our operations are available through a wide variety of sources and may be obtained through a wide variety of sources.

Patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, including duration

The Company possesses no patents or trademarks. The Company is not party to any agreement which would oblige the Company to pay any royalties.

On February 24, 2021 SYBLEU INC. ( the “Company”) and Oncology Pharma, Inc. ( “Licensee”) entered into an agreement whereby the Company granted the Licensee an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by the Company (“Agreement”).

 

This intellectual property relates to intratumoral administration of a combination of a chemotherapeutic agent and an immunomodulatory agent for cancer therapy ( “Cancer Therapy IP”). The concept of the Cancer Therapy IP is the simultaneous intratumoral injection of a chemotherapeutic agents in combination with immunomodulatory agents in sustained release formulations. The chemotherapeutic agent is for the purpose of directly killing the tumor cells for the release of antigens while the immunomodulatory protein or factor is to stimulate the antigenic response of the host to the antigens.

 

The term of the Agreement is fifteen years from the Effective Date.

 

Need for any government approval of principal products or services, effect of existing or probable governmental regulations on the business.

 

The US Food and Drug Administration (“FDA”) and foreign regulatory authorities will regulate our proposed products as drugs or biologics, , depending upon such factors as the use to which the product will be put, the chemical composition, and the interaction of the product on the human body. In the United States, products that are intended to be introduced into the body will generally be regulated as drugs, while tissues and cells intended for transplant into the human body will be generally be regulated as biologics.

 

Our domestic human drug and biological products will be subject to rigorous FDA review and approval procedures. After testing in animals, an Investigational New Drug Application (“IND”) must be filed with the FDA to obtain authorization for human testing. Extensive clinical testing, which is generally done in three phases, must then be undertaken at a hospital or medical center to demonstrate optimal use, safety, and efficacy of each product in humans.

 

10 
 

 

Phase I

 

Phase 1 trials are designed to assess the safety (pharmacovigilance), tolerability, pharmacokinetics, and pharmacodynamics of a drug. These trials are often conducted in an inpatient clinic, where the subject can be observed by full-time staff. The subject who receives the drug is usually observed until several half-lives of the drug have passed. Phase I trials normally include dose-ranging, also called dose escalation, studies so that the appropriate dose for therapeutic use can be found. The tested range of doses usually are a fraction of the dose that causes harm in animal testing and involve a small group of healthy volunteers. However, there are some circumstances when real patients are used, such as patients who have end-stage disease and lack other treatment options.

 

Phase II

 

Phase II trials are designed to assess how well the drug or biologic works, as well as to continue Phase I safety assessments in a larger group of volunteers and patients. Phase II trials are performed on larger groups.

 

Phase III

 

Phase III trials are aimed at being the definitive assessment of how effective the product is in comparison with current best standard treatment and to provide an adequate basis for physician labeling. Phase III trials may also be conducted for the purposes of (i) "label expansion" (to show the product works for additional types of patients/diseases beyond the original use for which the drug was approved for marketing or (ii) to obtain additional safety data, or to support marketing claims for the product.

 

On occasion Phase IV (Post Approval) trials may be required by the FDA. Phase IV trials involve the safety surveillance (pharmacovigilance) and ongoing technical support of a drug after it receives permission to be sold. The safety surveillance is designed to detect any rare or long-term adverse effects over a much larger patient population and longer time period than was possible during the Phase I-III clinical trials.

 

All phases, must be undertaken at a hospital or medical center to demonstrate optimal use, safety, and efficacy of each product in humans. Each clinical study is conducted under the auspices of an independent Institutional Review Board (“IRB”). The IRB will consider, among other things, ethical factors, the safety of human subjects, and the possible liability of the institution. The time and expense required to perform this clinical testing can far exceed the time and expense of the research and development initially required to create the product. No action can be taken to market any therapeutic product in the United States until an appropriate New Drug Application (“NDA”) or Biologic License Application (“BLA”) or has been approved by the FDA. FDA regulations also restrict the export of therapeutic products for clinical use prior to NDA or BLA approval.

 

Even after initial FDA approval has been obtained, further studies may be required to provide additional data on safety or to gain approval for the use of a product as a treatment for clinical indications other than those initially targeted. In addition, use of these products during testing and after marketing could reveal side effects that could delay, impede, or prevent FDA marketing approval, resulting in FDA-ordered product recall, or in FDA-imposed limitations on permissible

 

The FDA regulates the manufacturing process of pharmaceutical products, and human tissue and cell products, requiring that they be produced in compliance with Current Good Manufacturing Practices (“cGMP”) . The FDA also regulates the content of advertisements used to market pharmaceutical products. Generally, claims made in advertisements concerning the safety and efficacy of a product, or any advantages of a product over another product, must be supported by clinical data filed as part of an NDA or an amendment to an NDA, and statements regarding the use of a product must be consistent with the FDA approved labeling and dosage information for that product.

 

11 
 

 

Sales of drugs and biologics outside the United States are subject to foreign regulatory requirements that vary widely from country to country. Even if FDA approval has been obtained, approval of a product by comparable regulatory authorities of foreign countries must be obtained prior to the commencement of marketing the product in those countries. The time required to obtain such approval may be longer or shorter than that required for FDA approval.

 

Amount spent during the fiscal year ended June 30, 2021 on research and development activities

During the fiscal year ended June 30,2021 we expended $29,411 on research and development activities.

Costs and effects of compliance with environmental laws (federal, state and local)

SYBLEU has not incurred any unusual or significant costs to remain in compliance with any environmental laws and does not expect to incur any unusual or significant costs to remain in compliance with any environmental laws in the foreseeable future.

Number of total employees and number of full-time employees

As of September 20, 2021 the Company has 2 employees of which each of them is part time. 

 

Item 2. Properties

 

The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 provided to the Company by an entity controlled by the Company’s Chief Executive Officer on a month to month basis free of charge. The property is utilized as office space. We believe that the foregoing properties are adequate to meet our current needs for office space.

 

Item 3. Legal Proceedings

 

There are no material pending legal proceedings to which the Company is a party or of which any of the Company’s property is the subject. 

 

Item 4. Submission of Matters to a Vote of Security Holders

No matter was submitted during the fourth quarter of the fiscal year covered by this report to a vote of security holders, through the solicitation of proxies or otherwise.

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

There has never been and there currently is no public market for our securities. We anticipate applying for trading of our common stock on the Pink Market operated by OTC Markets Group , however, we can provide no assurance that our shares will be traded on the bulletin board or, if traded, that a public market will materialize.

 

The stockholders' equity section of the Company contains the following classes of capital stock as September 19, 2021:

 

Common stock, $ 0.0001 par value; 100,000,000 shares authorized: 10,418,000 shares issued and outstanding.

With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).

12 
 

On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation.

As of September 20, 2021 there were 245 holders of our Common Stock.

Dividends

No cash dividends were paid during the fiscal year ending June 30, 2021. We do not expect to declare cash dividends in the immediate future. 

Recent Sales of Unregistered Securities

On July 8, 2020 the Company issued 40,000 common shares to Dr. Stephen Hake as consideration for services

 

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares. A legend was placed on the certificate that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability and sale of the Shares.

 

On July 8, 2020 the Company issued 25,000 common shares to Dr. Jason Garber as consideration for services

 

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares. A legend was placed on the certificate that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability and sale of the Shares.

 

On November 9th 2020, the Company sold one million of its common shares (“Shares”) to The Stephen and Fredna Hake Trust DTD August 6, 2014 for consideration of $100,000. Dr. Stephen Hake, a Trustee of the Stephen and Fredna Hake Trust DTD August 6, 2014, serves as a member of the Scientific Advisory Board of the Company and has a pre-established relationship with the Company.

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares. A legend was placed on the certificate that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability and sale of the Shares.

The proceeds from the sale are being utilized by the Company for general corporate purposes.

Item 6. Selected Financial Data

As we are a “smaller reporting company” as defined by Rule 229.10(f)(1), we are not required to provide the information required by this Item.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 

 

As of June 30, 2021 we had Cash of $14,297 and as of June 30, 2020 we had Cash of $5,050.

13 
 

The increase in cash of approximately 183% is primarily attributable to sale of common stock for cash of $100,000 offset by expenses incurred in the operation of the Company’s business as well as net repayments of Notes Payable in the amount of $2,410.

As of June 30, 2021 we had Investment Securities of $185, 250 and as of June 30 , 2020 we had Investment Securities of $0.

The Company’s Investment Securities are attributable to 6,500 common shares of Oncology Pharma, Inc. paid to the Company pursuant to an agreement entered into by and between the Company and Oncology Pharma, Inc. whereby the Company granted Oncology Pharma, Inc. an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by the Company.

As of June 30, 2021 we had Prepaid Expenses of $0 and as of June 30, 2020 we had Prepaid Expenses of $3,500.

 

The decrease in Prepaid Expenses is attributable to completion of accounting services provided to the Company which had been prepaid in the prior period.

As of June 30,2021 we had Income Tax Payable of $21,394 and as of June 30, 2020 we had Income Tax Payable of $0.

Income Tax Payable as of the fiscal year ended 2021 is completely attributable to a tax provision recognized for income taxes payable in the calendar year ended December 31,2021.

As of June 30, 2021 we had Notes Payable Related Party of $8,919 a reduction of 21% as compared to Notes Payable, Related Party as of June 30, 2020. This reduction is attributable to net repayments of Notes Payable in the amount of $2,410 during the year ended June 30,2021.

As of June 30,2021 we had accrued expenses of $450( consisting of money owed to the Company’s Transfer Agent for services rendered) and as of June 30,2020 we had accrued expenses of $0.

Revenues from continuing operations were $177,450 for the year ended June 30, 2021 and Net Income was $71,552 for that period. Revenue was completely attributable to 6,500 common shares of Oncology Pharma, Inc. paid to the Company pursuant to an agreement entered into by and between the Company and Oncology Pharma, Inc. whereby the Company granted Oncology Pharma, Inc. an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by the Company. Operating Income for the year ended June 30, 2021 was $85,146. As the Company has only been in existence since June 12, 2020 no meaningful analysis of material changes in operations as compared to the prior year’s accounting period can be provided.

 

As of June 30, 2021 we had $27,002 in cash on hand and current liabilities of $30,763 such liabilities consisting of Income Tax Payable, Notes Payable, and Accrued Expenses. We feel we will not be able to satisfy our cash requirements over the next twelve months and shall be required to seek additional financing.

Management plans to raise additional funds by obtaining governmental and nongovernmental grants as well as offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings. Management can give no assurance that any governmental or nongovernmental grant will be obtained by the Company despite the Company’s best efforts.

As of June 30, 2021 the Company was not party to any binding agreements which would commit SYBLEU to any material capital expenditures.

 Item 7A. Quantitative and Qualitative Disclosures About Market Risk

As we are a smaller reporting company, as defined by Rule 229.10(f)(1), we are not required to provide the information required by this Item.

14 
 

Report of Independent Registered Public Accounting Firm

To the shareholders and the board of directors of SYBLEU INC.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of SYBLEU INC. (the "Company") as of June 30, 2021 and 2020, the related statements of operations, stockholders' equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company’s significant operating losses raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

/s/ BF Borgers CPA PC

BF Borgers CPA PC

 

We have served as the Company's auditor since 2020

Lakewood, CO

September 24, 2021

 

15 
 

SYBLEU INC.

BALANCE SHEETS    

 

           
   As of  As of
   June 30,2021  June 30,2020
ASSETS      
CURRENT ASSETS          
Cash  $14,297   $5,050 
Prepaid Expenses        3,500 
     Total Current Assets   14,297    8,550 
OTHER ASSETS          
Investment Securities   185250    0 
Total Other Assets   185250    0 
TOTAL ASSETS  $199,547   $8,550 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current Liabilities:          
Income Taxes Payable   21,394    0 
Notes Payable, Related Party   8,919    11,329 
Expenses Accrued but Unpaid   450    0 
Total Current Liabilities   30,763    11,329 
Total Liabilities  $30,763   $11,329 
           
STOCKHOLDERS' EQUITY (DEFICIT)          
Common Stock ($.0001 par value) 100,000,000 shares authorized; par value $0.0001  9,353,000 shares issued and outstanding as of June 30,2020 and 10,418,000 shares issued and outstanding as of June 30,2021   1,042    935 
Additional Paid in capital   100,049    145 
Retained Earnings (Deficit )   67,693    (3,859)
Total Stockholders' Equity (Deficit)   168,784    (2,779)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)  $199,547   $8,550 
           
The Accompanying Notes are an Integral Part of These Financial Statements

16 
 

SYBLEU INC.

STATEMENT OF OPERATIONS

 

            
   Year Ended June 30, 2021  Period from Inception (June 12,2020) to June 30, 2020
REVENUES       
License Fees   $177,450   $—   
TOTAL REVENUES   $177,450   $—   
COSTS AND EXPENSES           
Research and Development:           
Consulting Costs    26,311    2250 
Patent Application Costs    3,100    0 
Total Research and Development    29,411    2,250 
General and Administrative:           
Transfer Agency Fees    6,115    0 
Other General and Administrative Expenses    1,898    609 
Total General and Administrative    8,013    609 
Consulting:           
Legal Fees    500    0 
Accounting    11,880    0 
Other Consulting    13,600    0 
Website Development    —      1000 
Information Technology Consulting    23,900    0 
Total Consulting    49,880    1000 
Rent    5000    0 
Total Costs and Expenses    92,304    3,859 
            
OPERATING Income( LOSS)   $85,146   $(3,859)
            
OTHER INCOME AND EXPENSES           
Unrealized Gain ( Loss) on Investment Securities    7,800    0 
TOTAL OTHER INCOME ( EXPENSES)    7,800    0 
            
NET INCOME ( LOSS) Before taxes   $92,946   $(3,859)
Provision for Income Taxes    (21,394)   0 
NET INCOME ( LOSS)   $71,552   $(3,859)
BASIC AND FULLY DILUTED LOSS PER SHARE   $0.01   $(0.00)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING    10,054,932    9,353,000 
            
The Accompanying Notes are an Integral Part of These Financial Statements

  

17 
 

 

SYBLEU INC.

 STATEMENT OF SHAREHOLDERS EQUITY (DEFICIT)

For the year ended  June 30,2021

 

                          
   Common         
   Shares  Amount  Additional Paid in Capital 

Retained Earnings

(Deficit)

  Total
Balance July 1, 2020   93,53,000   $935   $145   $(3,859)  $(2,779)
Common shares issued for non employee services July 8,2020   65,000    7    4         11 
Net Loss Quarter ended September 30,2020        —    —    (21,896)   -21,896 
Balance September 30,2020   94,18,000   $942   $149   $(25,755)  $(24,664)
Common Shares issued for cash   November 9,2020   10,00,000   $100    99,900        $100,000 
Net Loss Quarter ended December 31,2020        —    —    (34,463)   -34,463 
Balance December 31,2020   1,04,18,000   $1,042   $1,00,049   $(60,218)  $40,873 
Net Income Quarter ended March 31,2021        —    —    89,716    89,716 
Balance March 31,2021   1,04,18,000   $1,042   $1,00,049   $29,498   $130,589 
Net Income Quarter ended June 30,2021        —    —    38,195    38,195 
Balance June 30, 2021   1,04,18,000   $1,042   $1,00,049   $67,693   $168,784 

 

 

                    
 The Accompanying Notes are an Integral Part of These Financial Statements

 

SYBLEU INC.

STATEMENT OF SHAREHOLDERS DEFICIT

For the period beginning with inception ( June 12, 2020) and ending  June 30,2020

                     

   Common         
   Shares  Amount  Additional Paid in Capital  Retained Deficit  Total
Balance June 12, 2020   —    —    —    —    — 
Common shares issued to Parent June 13,2020   93,53,000    935    145         1,080 
Net Loss                  (3,859)   (3,859)
Balance June 30, 2020   93,53,000    935   $145   $(3,859)  $(2,779)

 

 

                    
 The Accompanying Notes are an Integral Part of These Financial Statements

 

SYBLEU INC.

STATEMENT OF SHAREHOLDERS DEFICIT

 

 

18 
 

 

SYBLEU INC.

STATEMENT OF CASH FLOWS        

 

           
   Year Ended June 30, 2021  Period from inception ( June 12,2020) to June 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES          
Net Income (Loss)  $71,552   $(3,859)
Adjustments to reconcile net Income (loss) to net cash          
Common Stock Issued for payment of expenses   11    1,080 
Changes in Operating Assets and Liabilities          
(Increase) Decrease in Prepaid Expenses   3500    (3,500)
Increase (Decrease) in Accrued Expenses   450    0 
(Increase) Decrease in Securities accepted as  Payment   (177,450)   0 
Increase (Decrease) in Income Tax Payable   21,394    0 
Unrealized Loss ( Gain) in Investment Securities   (7,800)   0 
Net Cash provided by (used) in Operating Activities  $(88,343)   (6,279)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Increase ( Decrease)   in Notes Payable, Related Parties   (2,410)   11,329 
Common Stock issued for Cash   100,000    0 
           
Net Cash provided by (used) in Financing Activities   97,590    11,329 
           
Net Increase (Decrease) in Cash  $9,247    5,050 
           
Cash at Beginning of Period   5050    0 
Cash at End of Period  $14,297   $5,050 
           
Supplemental Cash Flow Information:          
Interest Paid   0    0 
Income Taxes Paid   0    0 
           
The Accompanying Notes are an Integral Part of These Condensed Financial Statements

  

19 
 

 

SYBLEU INC.

Notes to Financial Statements

As of June 30, 2021

  

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

SYBLEU INC. (“Company”) was organized June 12, 2020 under the laws of the State of Wyoming.

  

The Company intends to engage primarily in the development of regenerative medical applications up to the point of successful completion of Phase I and or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The primary factor to be considered by us in arriving at a decision to advance an application further to Phase III clinical trials would be a greater than anticipated indication of efficacy seen in Phase I trials.

 

A. BASIS OF ACCOUNTING

 

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a June 30 year-end.

 

B. USE OF ESTIMATES

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

C. CASH EQUIVALENTS

 

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

   

D. FAIR VALUE OF FINANCIAL INSTRUMENTS

 

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

 

Level 1:  Quoted prices in active markets for identical assets or liabilities

 

Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

 

Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

E. RESEARCH AND DEVELOPMENT COSTS

 

Research and development expenses relate primarily to the cost of discovery and research programs. Research and development costs are charged to expense as incurred. Research and development expenses consist mainly of evaluating potential Contract Research Organizations and filing of a provisional patent application.

 

20 
 

 


F. STOCK BASED COMPENSATION

 

Stock issued for Employee Compensation 

 

Stock based compensation to employees is accounted for at the award’s fair value at grant, less the amount (if any) paid by the award recipient.

 

During the year ended June 30,2021 no stock was issued for employee compensation.

 

Stock issued for Non-Employee Services

 

Stock Based compensation to non-employees is accounted for in accordance with ASC 505-50. ASC 505-50 requires entities to account for non-employee equity transactions based on either the fair value of the services received or the fair value of the equity instrument issued utilizing whichever measurement is most reliable. Stock issued for compensation to non employees during the quarter ended September 30, 2020 was accounted for at the fair value of the equity instruments issued as there were no dollar amounts billed to the Company for services rendered by the non employees.

 

In determining the Fair Value of shares issued as compensation, the Company took into account factors including the financial condition of the Company at the time of grant, the Company’s lack of profitability, the lack of cash sales of the Company’s stock, and the Company’s negative working capital as of the time of grant.

 

Pursuant to ASC 505-50-30-11505-50-30-11 an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date:

 

i.   The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and

 

ii.  

The date at which the counterparty’s performance is complete.

 

 

The Company has assessed that the date of issuance of the stock grant constituted commitment for performance therefore stock grants to non employees issued during the period were measured as of the issue date. The following summarizes the Company’s issuance of stock for non employee services for the quarter ended September 30, 2020:

 

      
Balance July 1, 2020   
Unvested Shares    0 
Vested Shares    0 
Total July 1, 2020    0 
Shares Issued Vested    65,000 
Balance September 30, 2020    65,000 


In determining Fair Value for shares issued to nonemployees an asset based valuation method was utilized , specifically Enterprise Value(Assets Less Cash and Cash Equivalents plus Fair Value of Debt) less Fair Value of Debt. The following inputs were utilized.

 

65,000 of the Common Shares of the Company issued on July 8, 2020:

 

     
Fair Value of Intellectual Property as of July 8, 2020   1,545 
Notes Payable as of July 8, 2020   13,329 
Enterprise Value as of July 8, 2020   14,874 
Less: Total Debt   (13,329)
Portion of Enterprise Value available to Common Shareholders   1,545 
Per Share Portion of Enterprise Value available to Common Shareholders  $0.000164 

 

21 
 

 

During the quarters ended December 31,2020, March 31, 2021 and June 30, 2020 no stock was issued for non- employee compensation.

G. INCOME TAXES

 

The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

 

The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2021 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

 

The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.

 

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

 

H.  BASIC EARNINGS (LOSS) PER SHARE

 

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.

 

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. There were no Common Stock Equivalents as of June 30, 2021.

 


NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS 

 

The Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification.

 

The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The Company has adopted the provisions of this ASU effective the fiscal year ended 2020. This guidance did not have a material impact on the Company’s Financial Statements.

 

22 
 

 

On February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (Topic 842). The ASU requires organizations that lease assets, referred to as "lessees," to recognize on the consolidated statement of financial position the rights and obligations created by those leases. The ASU also requires disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the consolidated financial statements. The ASU on leases became effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company has not adopted the provisions of this ASU. This guidance is not expected to have a material impact on the Company’s financial statements.

 

In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. This ASU is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with the accounting for employee share-based compensation. This ASU is effective for annual periods beginning after December 15, 2018 and interim periods within those annual periods, with early adoption permitted. The Company has not adopted the provisions of this ASU. This guidance is not expected to have a material impact on the Company’s financial statements.

 

NOTE 3. GOING CONCERN

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has generated minimal earnings during the period from June 12, 2020 (inception) through June 30,2021. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings.

 

On November 5th, 2020 the Company sold one million of its common shares (“Shares”) to The Stephen and Fredna Hake Trust DTD August 6, 2014 for consideration of $100,000. Dr. Stephen Hake, a Trustee of the Stephen and Fredna Hake Trust DTD August 6, 2014, serves as a member of the Scientific Advisory Board of the Company and has a pre-established relationship with the Company.

 

NOTE 4. RELATED PARTY TRANSACTIONS.

 

As of June30, 2021 the Company is indebted to David Koos, the Company’s Chairman and Chief Executive Officer, in the amount of  $1,879 ( “Koos Notes”).

 

As of June 30,2021 the Company is indebted to BST Partners, Inc. , a company controlled by David Koos, in the amount of $7,040 ( “BST Notes”)

 

Both the Koos Notes and BST Notes bear no interest and are due and payable upon demand of the Holder.

 

The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 provided to the Company by BST Partners, Inc. on a month to month basis free of charge. The property is utilized as office space. We believe that the foregoing properties are adequate to meet our current needs for office space. During the year ended June 30, 2021 the Company voluntarily paid $5,000 in rental expenses to BST Partner’s landlord on behalf of BST Partners, Inc.

 

23 
 

 

NOTE 5. NOTES PAYABLE RELATED PARTY

 

     
David Koos   1,879 
BST Partners   7,040 
Notes Payable, Related Parties  $8,919 

 

As of June 30, 2021 the Company is indebted to David R. Koos in the amount of $1,879.

 

As of June 30, 2021 the Company is indebted to BST Partners in the amount of $7,040.

 

BST Partners is controlled by David R. Koos.

 

NOTE 6. INVESTMENT SECURITIES

 

On March 11, 2021 the Company was paid 6,500 common shares of Oncology Pharma, Inc. pursuant to an agreement entered into by and between the Company and Oncology Pharma, Inc. whereby the Company granted Oncology Pharma, Inc. an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by the Company.

 

On June 30, 2021 the Company revalued 6,500 common shares of Oncology Pharma, Inc. at the closing price of the common shares on the OTC Pink market.

As of June 30, 2021:

6,500 Common shares of Oncolgy Pharma,Inc. 

                           
             
  Basis       Fair Value       Total Unrealized Gains       Net Unrealized Gain or (Loss) realized during the Quarter   ended June 30,2021  
$ 177,450     $ 185,250     $ 7,800     $ 51,350  

NOTE 7: INCOME TAXES

As of June 30, 2021

 

   
Deferred tax assets:   
Net operating tax carry forwards  $12,645 
Other   0 
Gross deferred tax assets   12,645 
Valuation allowance   (12,645)
Net deferred tax assets  $0 

 

As of June 30, 2020 the Company has a Deferred Tax Asset of $12,645 completely attributable to net operating loss carry forwards of approximately $60,219 generated during the calendar year ending December 31,2020   (which expire 20 years from the date the loss was incurred).

 

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain.

 

In addition, if as a result of a stock transfer or a reorganization, a corporation undergoes an “ownership change,” Code Section 382 limits the corporation’s right to use its NOLs each year thereafter to an annual percentage of the fair market value of the corporation at the time of the ownership change (the “Section 382 Limitation”).

 

A corporation is considered to undergo “an ownership change” if, as a result of changes in the stock ownership by “5-percent shareholders” or as a result of certain reorganizations, the percentage of the corporation’s stock owned by those 5-percent shareholders increases by more than 50 percentage points over the lowest percentage of stock owned by those shareholders at any time during the prior three-year testing period. Five-percent shareholders are persons who hold 5% or more of the stock of a corporation at any time during the testing period as well as certain groups of shareholders (based typically on whether they acquired their shares in a single offering or exchange transaction) who are not individually 5-percent shareholders.

 

24 
 

 

As the Company will require cash infusions in order to implement its business plan, and as it is probable, although not guaranteed, that such funding needs may be met through the sale of equity securities to “5-percent shareholders”, the Company recognized a valuation allowance equal to the deferred Tax Asset and the Company recorded a valuation allowance reducing all deferred tax assets to 0.

 

Income tax is calculated at the 21% Federal Corporate Rate.

 

NOTE 8. STOCKHOLDERS’ EQUITY

 

The stockholders’ equity section of the Company contains the following class of capital stock as of June 30, 2021:

 

Common stock, $ 0.0001 par value; 100,000,000 shares authorized: 10,418,000  shares issued and outstanding.

 

With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).

 

On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation.

 

NOTE 9. STOCK TRANSACTIONS

 

On July 7, 2020 the Company entered into an agreement with Dr. Stephen Hake whereby Dr. Hake agreed to serve as a member of the Company’s Scientific Advisory Board. Pursuant to the Agreement the Company is obligated to issue to Dr. Hake 40,000 of the Company’s common shares within 20 days of the execution of the Agreement.

 

On July 7, 2020 the Company entered into an agreement with Dr. Jason Garber whereby Dr. Garber agreed to serve as a member of the Company’s Scientific Advisory Board. Pursuant to the Agreement the Company is obligated to issue to Dr. Hake 25,000 of the Company’s common shares within 20 days of the execution of the Agreement.

 

On July 8, 2020 the Company issued 40,000 common shares to Dr. Stephen Hake

 

On July 8, 2020 the Company issued 25,000 common shares to Dr. Jason Garber.

 

On November 5th, 2020 SYBLEU INC. (the “Company”) sold one million of its common shares (“Shares”) for consideration of $100,000.

 

 

25 
 

 

 Item 9A. Controls and Procedures

 a) Evaluation of disclosure controls and procedures.

The principal executive officer and principal financial officer have evaluated the Company’s disclosure controls and procedures as of June 30, 2021. Based on this evaluation, they have concluded that the disclosure controls and procedures were effective to ensure that the information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms and to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. David Koos is the Company’s CEO and functions as the Company’s principal executive officer and principal financial officer respectively.

b) Management’s annual report on internal control over financial reporting.

Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) promulgated under the Securities and Exchange Act of 1934. Rule 13a-15(f) defines internal control over financial reporting as follows:

“The term internal control over financial reporting is defined as a process designed by, or under the supervision of, the issuer's principal executive and principal financial officers, or persons performing similar functions, and effected by the issuer's board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the issuer;

Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the issuer are being made only in accordance with authorizations of management and directors of the issuer; and

Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the issuer's assets that could have a material effect on the financial statements.”

The Company’s internal control over financial reporting is a process designed under the supervision of the Company’s management to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

In designing and evaluating our disclosure controls and procedures, our management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only a reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met.

The Company’s management assessed the effectiveness of its internal control over financial reporting as of June 30, 2021 is based on the framework in 2013 Committee of Sponsoring Organizations of the Treadway Commission, or COSO. Based on its assessment, management believes that, as of June 30,2021 the Company’s internal control over financial reporting is effective.

Management's report was not subject to attestation by the Company's registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the company to provide only management's report in this annual report. This exemption for smaller reporting companies provided under the temporary rules referenced above has been made permanent under Section 989G of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

26 
 

(c) There have been no changes during the quarter ended June 30, 2021 in the Company’s internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

Item 10. Directors, Executive Officers and Corporate Governance

 

David R. Koos

David R. Koos, 62 has served as Chairman of the Board of Directors, Chief Executive Officer, President, Secretary and Treasurer from inception to the date of this document. David R. Koos served as Chief Financial Officer since inception to July 21, 2020

Position:   Company Name:   Employment Dates:
Chairman, President, Chief Executive Officer, Secretary, Acting Chief Financial Officer, Principal Accounting Officer   Entest Group, Inc.   June 19, 2009 to November 28, 2018
Chairman, President, Chief Executive Officer, Secretary, Chief Financial Officer, Principal Accounting Officer   Entest BioMedical, Inc.( a California corporation)   August 22,2008 to the Present
Chairman and CEO   Regen BioPharma, Inc.   April 24, 2012 to January 22,2020
Acting CFO   Regen BioPharma, Inc.   April 24, 2012 to February 11, 2015
President   Regen BioPharma, Inc.   May 29, 2013 to October 9, 2013
Chairman, CEO   Zander Therapeutics, Inc.   February 2017 to January 22,2020
Sole Officer and Director   Cell Source Research, Inc.   March 24, 2003 to the Present
Chairman, President, CEO and Acting CFO   Bio-Matrix Scientific Group, Inc.   June 14, 2006 (Chairman) to July 31;2019 June 19, 2006 (President, CEO and Acting CFO); June 19, 2006 (Secretary) to July 31, 2019
Chairman & CEO   BST Partners Inc. (A California Corporation)   November 30, 2018 to the Present
Chairman & CEO   BST Partners Inc. (A Wyoming Corporation)   March 17, to 2017 to the Present
Chairman and Sole Officer   Regen Biopharma, Inc.   March 23,2021 to the Present
Chairman and Sole Officer   KCL Therapeutics, Inc.   March 23,2021 to the Present
Chairman and Sole Officer   Zander Therapeutics, Inc.   March 23,2021 to the Present

Joseph G. Vaini

Joseph G. Vaini, 59, has served as Chief Financial Officer since July21, 2020. For the past ten years Mr. Vaini has been a freelance independent consultant assisting microcap companies in complying with securities laws and regulation as well as assisting companies in the preparation of GAAP compliant financial statements. Over the past five years Mr. Vaini has provided consulting services to Bio- Matrix Scientific Group, Inc., Regen BioPharma, Inc., Entest Group, Inc., and Zander Therapeutics, Inc. Mr. Vaini does not possess a college degree. Mr. Vaini worked as a registered securities representative holding a Series 7 and Series 63 License between 1989 and 1995

Employment Agreements

Neither of David Koos or Joseph Vaini are party to an employment agreement with the Company and serve at the pleasure of the Board of Directors. 

27 
 

Code of Ethics

 

On July 20, 2020 we adopted a Code of Ethics pursuant to Section 406 of the Sarbanes-Oxley Act of 2002.

 

Director Independence

 

Audit Committee and Audit Committee Financial Expert

 

The members of the Company’s board of Directors may not be considered independent. The Company is not a "listed company" under Securities and Exchange Commission (“SEC”) rules and is therefore not required to have an audit committee comprised of independent directors. The Company does not currently have an audit committee, however, for certain purposes of the rules and regulations of the SEC and in accordance with the Sarbanes-Oxley Act of 2002, the Company’s  Board of Directors is deemed to be its  audit committee and as such functions as an audit committee and performs some of the same functions as an audit committee including: (1) selection and oversight of our independent accountant; (2) establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal controls and auditing matters; and (3) engaging outside advisors. The Board of Directors has determined that its member is able to read and understand fundamental financial statements and has substantial business experience that results in that member's financial sophistication. Accordingly, the Board of Directors believes that its member has the sufficient knowledge and experience necessary to fulfill the duties and obligations that an audit committee would have.

 

Nominating and Compensation Committees

 

The Company does not have standing nominating or compensation committees, or committees performing similar functions. The board of directors believes that it is not necessary to have a compensation committee at this time because the functions of such committee are adequately performed by the board of directors. The board of directors also is of the view that it is appropriate for the Company not to have a standing nominating committee because the board of directors has performed and will perform adequately the functions of a nominating committee. The Company is not a "listed company" under SEC rules and is therefore not required to have a compensation committee or a nominating committee.

 

Shareholder Communications

 

There has not been any defined policy or procedure requirements for stockholders to submit recommendations or nomination for directors. There are no specific, minimum qualifications that the board of directors believes must be met by a candidate recommended by the board of directors. Currently, the entire board of directors decides on nominees, on the recommendation of any member of the board of directors followed by the board’s review of the candidates’ resumes and interview of candidates. Based on the information gathered, the board of directors then makes a decision on whether to recommend the candidates as nominees for director. The Company does not pay any fee to any third party or parties to identify or evaluate or assist in identifying or evaluating potential nominee.

 

Because the Chief Executive Officer of the Company is also the Chairman of the Board of Directors of the Company, the Board of Directors has determined not to adopt a formal methodology for communications from shareholders on the belief that any communication would be brought to the Board of Directors’ attention by virtue of the co-extensive capacities of the Chairman of the Board of Directors.

 

28 
 

 

Executive Compensation

Name and Principal Position   Fiscal Year   Salary
($)		   Bonus
($)		   Stock Awards
($)		   Restricted Stock Awards
($)		   Option Awards
($)		   Non Equity Incentive Plan Compensation
($)		   Nonqualified Deferred Compensation Earnings
($)		   All Other Compensation
($)		   Total
($)
David Koos, Chairman, President, CEO, CFO (CFO inception to July 20, 2020)     2020       0       0       0       0       0       0       0       0       0  

 

Name and Principal Position   Fiscal Year   Salary
($)		   Bonus
($)		   Stock Awards
($)		   Restricted Stock Awards
($)		   Option Awards
($)		   Non Equity Incentive Plan Compensation
($)		   Nonqualified Deferred Compensation Earnings
($)		   All Other Compensation
($)		   Total
($)
Joseph G. Vaini CFO (since July 21, 2020)     2020       0       0       0       0       0       0       0       0       0  

  

Name and Principal Position   Fiscal Year   Salary
($)		   Bonus
($)		   Stock Awards
($)		   Restricted Stock Awards
($)		   Option Awards
($)		   Non Equity Incentive Plan Compensation
($)		   Nonqualified Deferred Compensation Earnings
($)		   All Other Compensation
($)		   Total
($)
David Koos, Chairman, President, CEO, CFO (CFO inception to July 20, 2020)     2021       0       0       0       0       0       0       0       0       0  

 

Name and Principal Position   Fiscal Year   Salary
($)		   Bonus
($)		   Stock Awards
($)		   Restricted Stock Awards
($)		   Option Awards
($)		   Non Equity Incentive Plan Compensation
($)		   Nonqualified Deferred Compensation Earnings
($)		   All Other Compensation
($)		   Total
($)
Joseph G. Vaini CFO (since July 21, 2020)     2021       0       0       0       0       0       0       0       0       0  

Employment Agreements

Currently the Company is not party to any employment agreement.

29 
 

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth information known to the Company with respect to the beneficial ownership of each class of the Company’s capital stock for (1) each person known by the Company to beneficially own more than 5% of each class of the Company’s voting securities, (2) each executive officer, (3) each of the Company’s directors and (4) all of the Company’s executive officers and directors as a group.

Based on 10,418,000 Common Shares outstanding as of September 20,2021

Title of Class  Name and Address of Beneficial Owner  Number of shares  Percentage
Common  David R. Koos   6112627    58.67%
   c/o SYBLEU INC          
Common  Joseph G Vaini   210790    2.02%
   c/o SYBLEU INC          
Common  Stephen Hake*   1040000    9.98%
   290 Saddle Run St. Henderson Nv          
Common  Timothy G Foat   850000    8.16%
   1204 Tangerine Street El Cajon CA          
Common  Heather Cassady   800000    7.68%
   1391 Broadway St Unit  B El Cajon CA          
Common  All Officers and Directors as a Group   6323417    60.70%
              
* Includes 1,000,000 Common Shares held by the The Stephen and Fredna Hake Trust DTD August 6, 2014  for which Dr. Hake serves as a Trustee

Item 13. Certain Relationships and Related Transactions, and Director Independence

On June 13, 2020 the Company issued 9,353,000 common shares to Cell Source Research, the Company’s sole shareholder and an entity under common control, for consideration consisting of payments made on behalf of the Company of $580 for incorporation expenses and of $500 of consulting expenses.

 

On July 14,2020 intellectual property controlled by the Company’s Chief Executive Officer and a corporation controlled by the Company’s Chief Executive Officer was assigned to the Company.

On December 2, 2020 SYBLEU INC. (the “Company”) was assigned all right, title, and interest to intellectual property related to intratumoral administration of a combination of a chemotherapeutic agent and an immunomodulatory agent for cancer therapy ( “Cancer Therapy IP”).


The concept of the Cancer Therapy IP is the simultaneous intratumoral injection of a chemotherapeutic agents in combination with immunomodulatory agents in sustained release formulations. The chemotherapeutic agent is for the purpose of directly killing the tumor cells for the release of antigens while the immunomodulatory protein or factor is to stimulate the antigenic response of the host to the antigens.

These rights were assigned to the Company by the Company’s Chief Executive Officer and Entest BioMedical, Inc., a California corporation controlled by the Company’s Chief Executive Officer. The aforementioned assignment constituted a contribution of intellectual property to the Company. There is no termination date of the assignment. No term or condition of the assignment would cause ownership of the intellectual property rights to revert back to David Koos and Entest BioMedical, Inc. No payment of any sort is required by to be made the Company to either David Koos or Entest BioMedical, Inc. pursuant to the assignment. The Company is not required to meet any particular benchmark or pay a royalty of any sort pursuant to this assignment.

As of June30, 2021 the Company is indebted to David Koos, the Company’s Chairman and Chief Executive Officer, in the amount of  $1,879 ( “Koos Notes”).

 

As of June 30,2021 the Company is indebted to BST Partners, Inc. , a company controlled by David Koos, in the amount of $7,040 ( “BST Notes”)

 

Both the Koos Notes and BST Notes bear no interest and are due and payable upon demand of the Holder.

 

The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 provided to the Company by BST Partners, Inc. on a month to month basis free of charge. The property is utilized as office space. During the year ended June 30, 2021 the Company voluntarily paid $5,000 in rental expenses to BST Partner’s landlord on behalf of BST Partners, Inc.

 

30 
 

 

 


Item 14. Principal Accounting Fees and Services

The following table sets forth the aggregate fees billed to us by BF Borgers CPA PC for the period beginning June 12, 2020 ( and ending September 30, 2019:

Audit Fees  $20,046 
Audit Related Fees   6,000 
Tax Fees   0 
All Other Fees   0 
   $26,046 

Audit Fees:  Aggregate fees billed for professional services rendered for the audit of the Company's annual financialstatements.

Audit Related Fees:    Aggregate fees billed for professional services rendered for assurance and related services that were reasonably related to the performance of the audit or review of our financial statements and are not reported under “Audit Fees” above. During the year ended September 30, 2019 these fees were primarily derived from review of financial statements in the Company's Form 10Q Reports.

 All services listed were pre-approved by the Board of Directors, functioning as the Audit Committee in accordance with Section 2(a) 3 of the Sarbanes-Oxley Act of 2002.


The following table sets forth the aggregate fees billed to us by BF Borgers CPA PC for the period beginning with inception and ending June 30, 2020:

Audit Fees  $0 
Audit Related Fees   0 
Tax Fees   0 
All Other Fees   0 
   $0 


The following table sets forth the aggregate fees billed to us by BF Borgers CPA PC for the period beginning July 1,2020 and ending June 30, 2021:

Audit Fees  $3000 
Audit Related Fees   5640 
Tax Fees   0 
All Other Fees   0 
   $8,640 

 

31 
 

 

Item 15. EXHIBITS 

 

Exhibit No. Description
31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes Oxley Act of 2002
31.2 Certification of Chief Financial Officer Pursuant to Section 3026 of the Sarbanes Oxley Act of 2002
32.1 Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes Oxley Act of 2002
32.2 Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes Oxley Act of 2002
3(i) Articles of Incorporation
3(ii) Bylaws
10.1 Agreement with Dr. Stephen Hake
10.2 Agreement with Dr. Jason Garber
10.3 $2,000 Promissory Note
10.4 $1,000 Promissory Note
10.5 $2,400 Promissory Note
10.6 $2,000 Promissory Note
10.7 $1,800 Promissory Note
10.8 $500 Promissory Note
10.9 $415 Promissory Note
10.10 $75 Promissory Note
10.11 $500 Promissory Note
10.12 $500 Promissory Note
10.13 $150 Promissory Note
10.14 $500 Promissory Note
10.15 $500 Promissory Note
10.16 $500 Promissory Note
10.17 $500 Promissory Note
10.18 $500 Promissory Note
10.19 $500 Promissory Note
10.20 $150 Promissory Note
10.21 Assignments (x)
10.22 Stock Purchase Agreement (y)
10.33 Assignment dated 12/2 (z)
10.34 $1,850 Promissory Note
10.35 $200 Promissory Note
10.36 $810 Promissory Note
10.37 $3,240 Promissory Note
10.38 License Agreement (aaa)

 

(a)   Incorporated by reference to Exhibit 3(i) of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(b)   Incorporated by reference to Exhibit 3(ii) of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(c)   Incorporated by reference to Exhibit 10.1 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(d)   Incorporated by reference to Exhibit 10.2 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(e)   Incorporated by reference to Exhibit 10.3 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(f)   Incorporated by reference to Exhibit 10.4 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(g)   Incorporated by reference to Exhibit 10.5 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(h)   Incorporated by reference to Exhibit 10.6 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(i)   Incorporated by reference to Exhibit 10.7 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(j)   Incorporated by reference to Exhibit 10.8 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(k)   Incorporated by reference to Exhibit 10.9 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(l)   Incorporated by reference to Exhibit 10.10 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(m)   Incorporated by reference to Exhibit 10.11 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(n)   Incorporated by reference to Exhibit 10.12 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(o)   Incorporated by reference to Exhibit 10.13 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(p)   Incorporated by reference to Exhibit 10.14 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(q)   Incorporated by reference to Exhibit 10.15 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(r)   Incorporated by reference to Exhibit 10.16 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(t)   Incorporated by reference to Exhibit 10.17 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(u)   Incorporated by reference to Exhibit 10.18 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(v)   Incorporated by reference to Exhibit 10.19 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(w)   Incorporated by reference to Exhibit 10.20 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(x)   Incorporated by reference to Exhibit 10.21 of the Company's Form 10-Q for the quarter ended September 31, 2020

 

(y)   Incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed November 9, 2020

 

(z)   Incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed December 4, 2020

 

(aaa)   Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K dated February 24,2021.

 

32 
 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    SYBLEU INC.
     
  By: /s/ David R. Koos
  Name: David R. Koos
  Title: Chairman, Chief Executive Officer, Director
  Date: September 24, 2021

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    SYBLEU INC.
     
  By: /s/ Joseph G. Vaini
  Name: Joseph G. Vaini
  Title: Chief Financial Officer
  Date: September 24, 2021

33 
 

 EX-101.SCH 2 cik0001818674-20210630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - STATEMENT OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - STATEMENT OF SHAREHOLDERS EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - STATEMENT OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - NOTES PAYABLE RELATED PARTY link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - INVESTMENT SECURITIES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - STOCK TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - NOTES PAYABLE RELATED PARTY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - INVESTMENT SECURITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - NOTES PAYABLE RELATED PARTY (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - NOTES PAYABLE RELATED PARTY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - INVESTMENT SECURITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - INVESTMENT SECURITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - STOCK TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 3 cik0001818674-20210630_cal.xml XBRL CALCULATION FILE EX-101.DEF 4 cik0001818674-20210630_def.xml XBRL DEFINITION FILE EX-101.LAB 5 cik0001818674-20210630_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Related Party [Axis] Stephen Hake [Member] David R Koos [Member] B S T Partners [Member] Series [Axis] Oncology Pharma Inc [Member] Dr Stephen Hake [Member] Dr Jason Garber [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash Prepaid Expenses      Total Current Assets OTHER ASSETS Investment Securities Total Other Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Income Taxes Payable Notes Payable, Related Party Expenses Accrued but Unpaid Total Current Liabilities Total Liabilities STOCKHOLDERS' EQUITY (DEFICIT) Common Stock ($.0001 par value) 100,000,000 shares authorized; par value $0.0001  9,353,000 shares issued and outstanding as of June 30,2020 and 10,418,000 shares issued and outstanding as of June 30,2021 Additional Paid in capital Retained Earnings (Deficit ) Total Stockholders' Equity (Deficit) TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) Common stock, shares authorized Common stock, par value Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] REVENUES License Fees TOTAL REVENUES COSTS AND EXPENSES Research and Development: Consulting Costs Patent Application Costs Total Research and Development General and Administrative: Transfer Agency Fees Other General and Administrative Expenses Total General and Administrative Consulting: Legal Fees Accounting Other Consulting Website Development Information Technology Consulting Total Consulting Rent Total Costs and Expenses OPERATING Income( LOSS) OTHER INCOME AND EXPENSES Unrealized Gain ( Loss) on Investment Securities TOTAL OTHER INCOME ( EXPENSES) NET INCOME ( LOSS) Before taxes Provision for Income Taxes NET INCOME ( LOSS) BASIC AND FULLY DILUTED LOSS PER SHARE WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Statement [Table] Statement [Line Items] Beginning balance, value Balance at beginning, shares Common shares issued to Parent June 13,2020 Common shares issued toParent June 13,2020, share Common Shares issued for cash   November 9,2020 Stock Issued During Period, Shares, New Issues Common shares issued for non employee services July 8,2020 Stock Issued During Period, Shares, Issued for Services Net Loss Ending balance, value Balance at ending, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net Income (Loss) Adjustments to reconcile net Income (loss) to net cash Common Stock Issued for payment of expenses Changes in Operating Assets and Liabilities (Increase) Decrease in Prepaid Expenses Increase (Decrease) in Accrued Expenses (Increase) Decrease in Securities accepted as  Payment Increase (Decrease) in Income Tax Payable Unrealized Loss ( Gain) in Investment Securities Net Cash provided by (used) in Operating Activities CASH FLOWS FROM FINANCING ACTIVITIES Increase ( Decrease)   in Notes Payable, Related Parties Common Stock issued for Cash Net Cash provided by (used) in Financing Activities Net Increase (Decrease) in Cash Cash at Beginning of Period Cash at End of Period Supplemental Cash Flow Information: Interest Paid Income Taxes Paid Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Accounting Changes and Error Corrections [Abstract] RECENT ACCOUNTING PRONOUNCEMENTS GOING CONCERN Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Debt Disclosure [Abstract] NOTES PAYABLE RELATED PARTY Schedule of Investments [Abstract] INVESTMENT SECURITIES Income Tax Disclosure [Abstract] INCOME TAXES Equity [Abstract] STOCKHOLDERS’ EQUITY Stock Transactions STOCK TRANSACTIONS BASIS OF ACCOUNTING USE OF ESTIMATES CASH EQUIVALENTS FAIR VALUE OF FINANCIAL INSTRUMENTS RESEARCH AND DEVELOPMENT COSTS STOCK BASED COMPENSATION INCOME TAXES BASIC EARNINGS (LOSS) PER SHARE Schedule Of Issuance Of Stock For Non employee Services Schedule Of Valuation Method Of Fair Value Of Unvested Shares Schedule of related party debt Schedule Of Common Shares Schedule of Deferred Tax Assets Unvested Shares at beginning Vested Shares Total Shares Issued For Non Employee Services Shares issued vested Ending balnce, shares Fair Value of Intellectual Property as of July 8, 2020 Notes Payable as of July 8, 2020 Enterprise Value as of July 8, 2020 Less: Total Debt Portion of Enterprise Value available to Common Shareholders Per Share Portion of Enterprise Value available to Common Shareholders Schedule of Defined Benefit Plans Disclosures [Table] Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items] Proceeds from sale of common stock Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Proceeds from related debt Notes Payable, Related Parties Schedule of Investments [Table] Schedule of Investments [Line Items] Investment Securities, Basis Investment Securities, Fair Value Investment Securities, Total Unrealized Losses Investment Securities, Net Unrealized Gain or (Loss) realized Number of shares issued for property dividend Deferred tax assets: Net operating tax carry forwards Other Gross deferred tax assets Valuation allowance Net deferred tax assets Deferred Tax Asset Net operating loss carry forwards Federal Corporate Rate Common Stock par value Common Stock shares authorized Common Stock shares issued Common Stock shares outstanding Common stock issued Assets, Current Other Assets Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Revenues Research and Development Expense General and Administrative Expense ConsultingNet Operating Income (Loss) Other Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Tax Expense (Benefit) Shares, Outstanding CommonStockIssuedForPaymentOfExpenses Increase (Decrease) in Prepaid Expense Increase (Decrease) in Collateral Held under Securities Lending Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash and Cash Equivalents, at Carrying Value Income Tax, Policy [Policy Text Block] Debt, Current Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance EX-101.PRE 6 cik0001818674-20210630_pre.xml XBRL PRESENTATION FILE EX-31.1 7 ex31_1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, David Koos, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of Sybleu Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: September 24, 2021 By: /s/  David R. Koos
    David R. Koos 
Chief Executive Officer

 

 EX-31.2 8 ex31_2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Joseph G. Vaini, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of Sybleu Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: September 24, 2021 By: /s/  Joseph G. Vaini
    Joseph G. Vaini
    Principal Financial Officer

 

 

 

 

 EX-32.1 9 ex32_1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Annual report of Sybleu Inc. (the “Company”) on Form 10-K for the year ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: September 24, 2021 By: /s/  David R. Koos
    David R. Koos 
Chief Executive Officer

 

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002, or other document authentications, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Sybleu Inc. and will be retained by Sybleu Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

 EX-32.2 10 ex32_2.htm EXHIBIT 32.2

EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Annual report of Sybleu Inc.(the “Company”) on Form 10-K for the year ended June 30, 2021, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: September 24, 2021 By: /s/  Joseph G. Vaini
    Joseph G. Vaini 
Principal Financial Officer

 

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002, or other document authentications, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Sybleu Inc. and will be retained by Sybleu Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

 XML 11 sybleu063021form10k_htm.xml IDEA: XBRL DOCUMENT 0001818674 2020-07-01 2021-06-30 0001818674 2021-09-20 0001818674 2021-06-30 0001818674 2020-06-30 0001818674 2020-06-13 2020-06-30 0001818674 us-gaap:CommonStockMember 2020-06-30 0001818674 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001818674 us-gaap:RetainedEarningsMember 2020-06-30 0001818674 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001818674 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001818674 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001818674 2020-07-01 2020-09-30 0001818674 us-gaap:CommonStockMember 2020-09-30 0001818674 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001818674 us-gaap:RetainedEarningsMember 2020-09-30 0001818674 2020-09-30 0001818674 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001818674 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001818674 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001818674 2020-10-01 2020-12-31 0001818674 us-gaap:CommonStockMember 2020-12-31 0001818674 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001818674 us-gaap:RetainedEarningsMember 2020-12-31 0001818674 2020-12-31 0001818674 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001818674 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001818674 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001818674 2021-01-01 2021-03-31 0001818674 us-gaap:CommonStockMember 2021-03-31 0001818674 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001818674 us-gaap:RetainedEarningsMember 2021-03-31 0001818674 2021-03-31 0001818674 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001818674 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001818674 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001818674 2021-04-01 2021-06-30 0001818674 us-gaap:CommonStockMember 2021-06-30 0001818674 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001818674 us-gaap:RetainedEarningsMember 2021-06-30 0001818674 us-gaap:CommonStockMember 2020-06-12 0001818674 us-gaap:AdditionalPaidInCapitalMember 2020-06-12 0001818674 us-gaap:RetainedEarningsMember 2020-06-12 0001818674 2020-06-12 0001818674 us-gaap:CommonStockMember 2020-06-13 2020-06-30 0001818674 us-gaap:AdditionalPaidInCapitalMember 2020-06-13 2020-06-30 0001818674 us-gaap:RetainedEarningsMember 2020-06-13 2020-06-30 0001818674 2021-07-08 0001818674 CIK0001818674:StephenHakeMember 2020-11-01 2020-11-05 0001818674 CIK0001818674:DavidRKoosMember 2020-07-01 2021-06-30 0001818674 CIK0001818674:BSTPartnersMember 2020-07-01 2021-06-30 0001818674 CIK0001818674:DavidRKoosMember 2021-06-30 0001818674 CIK0001818674:BSTPartnersMember 2021-06-30 0001818674 CIK0001818674:OncologyPharmaIncMember 2021-03-01 2021-03-11 0001818674 CIK0001818674:OncologyPharmaIncMember 2020-07-01 2021-06-30 0001818674 CIK0001818674:OncologyPharmaIncMember 2021-06-30 0001818674 CIK0001818674:DrStephenHakeMember 2020-07-01 2020-07-08 0001818674 CIK0001818674:DrJasonGarberMember 2020-07-01 2020-07-08 iso4217:USD shares iso4217:USD shares pure 0001818674 false --06-30 2021 FY 10-K true 2021-06-30 false 333-248059 SYBLEU INC WY 85-1412307 4700 Spring Street Suite 304 La Mesa CA 91942 619 227-9192 No No No Non-accelerated Filer true false false No 0 10418000 14297 5050 3500 14297 8550 185250 0 185250 0 199547 8550 21394 0 8919 11329 450 0 30763 11329 30763 11329 100000000 100000000 0.0001 0.0001 9353000 9353000 10418000 10418000 1042 935 100049 145 67693 -3859 168784 -2779 199547 8550 177450 177450 26311 2250 3100 0 29411 2250 6115 0 1898 609 8013 609 500 0 11880 0 13600 0 1000 23900 0 49880 1000 5000 0 92304 3859 85146 -3859 7800 0 7800 0 92946 -3859 21394 -0 71552 -3859 0.01 -0.00 10054932 9353000 9353000 935 145 -3859 -2779 65000 7 4 11 -21896 -21896 9418000 942 149 -25755 -24664 1000000 100 99900 100000 -34463 -34463 10418000 1042 100049 -60218 40873 89716 89716 10418000 1042 100049 29498 130589 38195 38195 10418000 1042 100049 67693 168784 9353000 935 145 1080 -3859 -3859 9353000 935 145 -3859 -2779 71552 -3859 -11 -1080 -3500 3500 450 0 -177450 0 21394 0 7800 -0 -88343 -6279 -2410 11329 100000 0 97590 11329 9247 5050 5050 0 14297 5050 0 0 0 0 <p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zHm68CdLjwgd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 1. <span id="xdx_829_zbibU1SnbVqh">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">SYBLEU INC. (“Company”) was organized June 12, 2020 under the laws of the State of Wyoming.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company intends to engage primarily in the development of regenerative medical applications up to the point of successful completion of Phase I and or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The primary factor to be considered by us in arriving at a decision to advance an application further to Phase III clinical trials would be a greater than anticipated indication of efficacy seen in Phase I trials.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zMaSHUw57Hdj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">A. <span id="xdx_86B_z00htYVP9fth">BASIS OF ACCOUNTING</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a June 30 year-end.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_846_eus-gaap--UseOfEstimates_zSk2jIWmEGEe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">B. <span id="xdx_868_z3UgBIb8lWye">USE OF ESTIMATES</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zX32K322AmLf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">C. <span id="xdx_863_zSS1s4PAmk46">CASH EQUIVALENTS</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">   </span></p> <p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zosnfeuHj15b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">D. <span id="xdx_862_z2LZ0jNG8dX">FAIR VALUE OF FINANCIAL INSTRUMENTS</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Level 1:  Quoted prices in active markets for identical assets or liabilities</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zNn0iQyPBQa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">E. <span id="xdx_86B_z9gsqqu0RvPk">RESEARCH AND DEVELOPMENT COSTS</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Research and development expenses relate primarily to the cost of discovery and research programs. Research and development costs are charged to expense as incurred. Research and development expenses consist mainly of evaluating potential Contract Research Organizations and filing of a provisional patent application.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"/> <p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zr9YBPpIm6uh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><br/> F. <span id="xdx_868_z0G6PcO0YIBi">STOCK BASED COMPENSATION</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Stock issued for Employee Compensation </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Stock based compensation to employees is accounted for at the award’s fair value at grant, less the amount (if any) paid by the award recipient.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During the year ended June 30,2021 no stock was issued for employee compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Stock issued for Non-Employee Services</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Stock Based compensation to non-employees is accounted for in accordance with ASC 505-50. ASC 505-50 requires entities to account for non-employee equity transactions based on either the fair value of the services received or the fair value of the equity instrument issued utilizing whichever measurement is most reliable. Stock issued for compensation to non employees during the quarter ended September 30, 2020 was accounted for at the fair value of the equity instruments issued as there were no dollar amounts billed to the Company for services rendered by the non employees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In determining the Fair Value of shares issued as compensation, the Company took into account factors including the financial condition of the Company at the time of grant, the Company’s lack of profitability, the lack of cash sales of the Company’s stock, and the Company’s negative working capital as of the time of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant to ASC 505-50-30-11505-50-30-11 an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20px; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">i.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 7px"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20px; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">ii.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 7px"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The date at which the counterparty’s performance is complete.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company has assessed that the date of issuance of the stock grant constituted commitment for performance therefore stock grants to non employees issued during the period were measured as of the issue date. The following summarizes the Company’s issuance of stock for non employee services for the quarter ended September 30, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--ScheduleOfIssuanceOfStockForNonemployeeServices_z9NrX3kFi4qd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"><span id="xdx_8B9_zUKPqjEVbHV5" style="display: none">Schedule Of Issuance Of Stock For Non employee Services</span></td><td style="vertical-align: top; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left; font-weight: bold; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Balance July 1, 2020</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 44%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Unvested Shares</span></td><td style="vertical-align: top; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 10%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_981_ecustom--UnvestedSharesForNonEmployeeServices_iI_c20200630_zaBqDaC7DUrd" style="width: 43%; text-align: right" title="Unvested Shares at beginning"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Vested Shares</span></td><td style="vertical-align: top; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--VestedSharesForNonEmployeeServices_iI_c20200630_zIDvrOToG1Ie" style="text-align: right" title="Vested Shares"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Total July 1, 2020</b></span></td><td style="vertical-align: top; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--TotalSharesIssuedForNonEmployeeServices_uShares_c20200701__20200930_zek5i3GCmVac" style="font-weight: bold; text-align: right" title="Total Shares Issued For Non Employee Services"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Shares Issued Vested</span></td><td style="vertical-align: top; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--SharesIssuedVestedDuringPeriodForNonEmployeeServices_c20200701__20200930_zLh0li2g0jya" style="text-align: right" title="Shares issued vested"><span style="font: 10pt Times New Roman, Times, Serif">65,000</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Balance September 30, 2020</b></span></td><td style="vertical-align: top; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--StockIssuedDuringPeriodSharesIssuedForNonEmployeeServices_c20200701__20200930_zjAUBayjyKl5" style="font-weight: bold; text-align: right" title="Ending balnce, shares"><span style="font: 10pt Times New Roman, Times, Serif">65,000</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A0_zldYqrQRAwYj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><br/> In determining Fair Value for shares issued to nonemployees an asset based valuation method was utilized , specifically Enterprise Value(Assets Less Cash and Cash Equivalents plus Fair Value of Debt) less Fair Value of Debt. The following inputs were utilized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">65,000 of the Common Shares of the Company issued on July 8, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfValuationMethodOfFairValueOfUnvestedShares_z29bdNvlT40a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_8BC_zvpw6If7jBsg" style="display: none">Schedule Of Valuation Method Of Fair Value Of Unvested Shares</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20210708_zTPBW1V5EcRk" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_zJRUXk91IME3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Fair Value of Intellectual Property as of July 8, 2020</span></td><td style="width: 10%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 18%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,545</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--NotesPayable_iI_zCVefhUM6Rb7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Notes Payable as of July 8, 2020</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">13,329</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_ecustom--EnterpriseValue_iI_zpDRYtYXct6c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Enterprise Value as of July 8, 2020</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">14,874</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--DebtCurrent_iNI_di_zO0UuajM5TK9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Less: Total Debt</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(13,329</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_400_ecustom--PortionOfEnterpriseValueAvailableToCommonShareholders_iI_z7nynqiNRz1b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Portion of Enterprise Value available to Common Shareholders</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,545</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_ecustom--PerSharePortionOfEnterpriseValueAvailableToCommonShareholders_iI_zAaDfhmf9zR8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Per Share Portion of Enterprise Value available to Common Shareholders</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.000164</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A0_zGfDeeYAqPWb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><span style="font: 10pt Times New Roman, Times, Serif">During the quarters ended December 31,2020, March 31, 2021 and June 30, 2020 no stock was issued for non- employee compensation.</span></p> <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zMysH31PDdr3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">G. <span id="xdx_86E_zZOUxYcrgdd3">INCOME TAXES</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2021 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zjsp8cP1Khjl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">H.  <span id="xdx_864_zynGipNELgx7">BASIC EARNINGS (LOSS) PER SHARE</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. There were no Common Stock Equivalents as of June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zMaSHUw57Hdj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">A. <span id="xdx_86B_z00htYVP9fth">BASIS OF ACCOUNTING</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a June 30 year-end.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_846_eus-gaap--UseOfEstimates_zSk2jIWmEGEe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">B. <span id="xdx_868_z3UgBIb8lWye">USE OF ESTIMATES</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zX32K322AmLf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">C. <span id="xdx_863_zSS1s4PAmk46">CASH EQUIVALENTS</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">   </span></p> <p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zosnfeuHj15b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">D. <span id="xdx_862_z2LZ0jNG8dX">FAIR VALUE OF FINANCIAL INSTRUMENTS</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Level 1:  Quoted prices in active markets for identical assets or liabilities</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zNn0iQyPBQa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">E. <span id="xdx_86B_z9gsqqu0RvPk">RESEARCH AND DEVELOPMENT COSTS</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Research and development expenses relate primarily to the cost of discovery and research programs. Research and development costs are charged to expense as incurred. Research and development expenses consist mainly of evaluating potential Contract Research Organizations and filing of a provisional patent application.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"/> <p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zr9YBPpIm6uh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><br/> F. <span id="xdx_868_z0G6PcO0YIBi">STOCK BASED COMPENSATION</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Stock issued for Employee Compensation </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Stock based compensation to employees is accounted for at the award’s fair value at grant, less the amount (if any) paid by the award recipient.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During the year ended June 30,2021 no stock was issued for employee compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Stock issued for Non-Employee Services</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Stock Based compensation to non-employees is accounted for in accordance with ASC 505-50. ASC 505-50 requires entities to account for non-employee equity transactions based on either the fair value of the services received or the fair value of the equity instrument issued utilizing whichever measurement is most reliable. Stock issued for compensation to non employees during the quarter ended September 30, 2020 was accounted for at the fair value of the equity instruments issued as there were no dollar amounts billed to the Company for services rendered by the non employees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In determining the Fair Value of shares issued as compensation, the Company took into account factors including the financial condition of the Company at the time of grant, the Company’s lack of profitability, the lack of cash sales of the Company’s stock, and the Company’s negative working capital as of the time of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant to ASC 505-50-30-11505-50-30-11 an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20px; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">i.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 7px"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20px; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">ii.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 7px"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The date at which the counterparty’s performance is complete.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company has assessed that the date of issuance of the stock grant constituted commitment for performance therefore stock grants to non employees issued during the period were measured as of the issue date. The following summarizes the Company’s issuance of stock for non employee services for the quarter ended September 30, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--ScheduleOfIssuanceOfStockForNonemployeeServices_z9NrX3kFi4qd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"><span id="xdx_8B9_zUKPqjEVbHV5" style="display: none">Schedule Of Issuance Of Stock For Non employee Services</span></td><td style="vertical-align: top; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left; font-weight: bold; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Balance July 1, 2020</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 44%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Unvested Shares</span></td><td style="vertical-align: top; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 10%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_981_ecustom--UnvestedSharesForNonEmployeeServices_iI_c20200630_zaBqDaC7DUrd" style="width: 43%; text-align: right" title="Unvested Shares at beginning"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Vested Shares</span></td><td style="vertical-align: top; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--VestedSharesForNonEmployeeServices_iI_c20200630_zIDvrOToG1Ie" style="text-align: right" title="Vested Shares"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Total July 1, 2020</b></span></td><td style="vertical-align: top; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--TotalSharesIssuedForNonEmployeeServices_uShares_c20200701__20200930_zek5i3GCmVac" style="font-weight: bold; text-align: right" title="Total Shares Issued For Non Employee Services"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Shares Issued Vested</span></td><td style="vertical-align: top; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--SharesIssuedVestedDuringPeriodForNonEmployeeServices_c20200701__20200930_zLh0li2g0jya" style="text-align: right" title="Shares issued vested"><span style="font: 10pt Times New Roman, Times, Serif">65,000</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Balance September 30, 2020</b></span></td><td style="vertical-align: top; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--StockIssuedDuringPeriodSharesIssuedForNonEmployeeServices_c20200701__20200930_zjAUBayjyKl5" style="font-weight: bold; text-align: right" title="Ending balnce, shares"><span style="font: 10pt Times New Roman, Times, Serif">65,000</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A0_zldYqrQRAwYj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><br/> In determining Fair Value for shares issued to nonemployees an asset based valuation method was utilized , specifically Enterprise Value(Assets Less Cash and Cash Equivalents plus Fair Value of Debt) less Fair Value of Debt. The following inputs were utilized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">65,000 of the Common Shares of the Company issued on July 8, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfValuationMethodOfFairValueOfUnvestedShares_z29bdNvlT40a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_8BC_zvpw6If7jBsg" style="display: none">Schedule Of Valuation Method Of Fair Value Of Unvested Shares</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20210708_zTPBW1V5EcRk" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_zJRUXk91IME3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Fair Value of Intellectual Property as of July 8, 2020</span></td><td style="width: 10%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 18%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,545</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--NotesPayable_iI_zCVefhUM6Rb7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Notes Payable as of July 8, 2020</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">13,329</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_ecustom--EnterpriseValue_iI_zpDRYtYXct6c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Enterprise Value as of July 8, 2020</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">14,874</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--DebtCurrent_iNI_di_zO0UuajM5TK9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Less: Total Debt</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(13,329</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_400_ecustom--PortionOfEnterpriseValueAvailableToCommonShareholders_iI_z7nynqiNRz1b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Portion of Enterprise Value available to Common Shareholders</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,545</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_ecustom--PerSharePortionOfEnterpriseValueAvailableToCommonShareholders_iI_zAaDfhmf9zR8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Per Share Portion of Enterprise Value available to Common Shareholders</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.000164</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A0_zGfDeeYAqPWb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><span style="font: 10pt Times New Roman, Times, Serif">During the quarters ended December 31,2020, March 31, 2021 and June 30, 2020 no stock was issued for non- employee compensation.</span></p> <table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--ScheduleOfIssuanceOfStockForNonemployeeServices_z9NrX3kFi4qd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"><span id="xdx_8B9_zUKPqjEVbHV5" style="display: none">Schedule Of Issuance Of Stock For Non employee Services</span></td><td style="vertical-align: top; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left; font-weight: bold; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Balance July 1, 2020</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 44%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Unvested Shares</span></td><td style="vertical-align: top; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 10%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_981_ecustom--UnvestedSharesForNonEmployeeServices_iI_c20200630_zaBqDaC7DUrd" style="width: 43%; text-align: right" title="Unvested Shares at beginning"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Vested Shares</span></td><td style="vertical-align: top; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--VestedSharesForNonEmployeeServices_iI_c20200630_zIDvrOToG1Ie" style="text-align: right" title="Vested Shares"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Total July 1, 2020</b></span></td><td style="vertical-align: top; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--TotalSharesIssuedForNonEmployeeServices_uShares_c20200701__20200930_zek5i3GCmVac" style="font-weight: bold; text-align: right" title="Total Shares Issued For Non Employee Services"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Shares Issued Vested</span></td><td style="vertical-align: top; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--SharesIssuedVestedDuringPeriodForNonEmployeeServices_c20200701__20200930_zLh0li2g0jya" style="text-align: right" title="Shares issued vested"><span style="font: 10pt Times New Roman, Times, Serif">65,000</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Balance September 30, 2020</b></span></td><td style="vertical-align: top; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--StockIssuedDuringPeriodSharesIssuedForNonEmployeeServices_c20200701__20200930_zjAUBayjyKl5" style="font-weight: bold; text-align: right" title="Ending balnce, shares"><span style="font: 10pt Times New Roman, Times, Serif">65,000</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> 0 0 0 65000 65000 <table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfValuationMethodOfFairValueOfUnvestedShares_z29bdNvlT40a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_8BC_zvpw6If7jBsg" style="display: none">Schedule Of Valuation Method Of Fair Value Of Unvested Shares</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20210708_zTPBW1V5EcRk" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_zJRUXk91IME3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Fair Value of Intellectual Property as of July 8, 2020</span></td><td style="width: 10%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 18%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,545</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--NotesPayable_iI_zCVefhUM6Rb7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Notes Payable as of July 8, 2020</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">13,329</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_ecustom--EnterpriseValue_iI_zpDRYtYXct6c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Enterprise Value as of July 8, 2020</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">14,874</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--DebtCurrent_iNI_di_zO0UuajM5TK9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Less: Total Debt</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(13,329</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_400_ecustom--PortionOfEnterpriseValueAvailableToCommonShareholders_iI_z7nynqiNRz1b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Portion of Enterprise Value available to Common Shareholders</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,545</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_ecustom--PerSharePortionOfEnterpriseValueAvailableToCommonShareholders_iI_zAaDfhmf9zR8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Per Share Portion of Enterprise Value available to Common Shareholders</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.000164</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> 1545 13329 14874 13329 1545 0.000164 <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zMysH31PDdr3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">G. <span id="xdx_86E_zZOUxYcrgdd3">INCOME TAXES</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2021 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zjsp8cP1Khjl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">H.  <span id="xdx_864_zynGipNELgx7">BASIC EARNINGS (LOSS) PER SHARE</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. There were no Common Stock Equivalents as of June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_80C_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zMpKwz8XK0Id" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><br/> <b>NOTE 2</b>. <b><span id="xdx_822_zGLB3Qhbai43">RECENT ACCOUNTING PRONOUNCEMENTS</span></b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The Company has adopted the provisions of this ASU effective the fiscal year ended 2020. This guidance did not have a material impact on the Company’s Financial Statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (Topic 842). The ASU requires organizations that lease assets, referred to as "lessees," to recognize on the consolidated statement of financial position the rights and obligations created by those leases. The ASU also requires disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the consolidated financial statements. The ASU on leases became effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company has not adopted the provisions of this ASU. This guidance is not expected to have a material impact on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In June 2018, the FASB issued ASU No. 2018-07, <i>Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting.</i> This ASU is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with the accounting for employee share-based compensation. This ASU is effective for annual periods beginning after December 15, 2018 and interim periods within those annual periods, with early adoption permitted. The Company has not adopted the provisions of this ASU. This guidance is not expected to have a material impact on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_802_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zzci9QTldOfh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 3. <span id="xdx_823_zyZLRbuato11">GOING CONCERN</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has generated minimal earnings during the period from June 12, 2020 (inception) through June 30,2021. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On November 5th, 2020 the Company sold one million of its common shares (“Shares”) to The Stephen and Fredna Hake Trust DTD August 6, 2014 for consideration of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20201101__20201105__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StephenHakeMember_zVYOW9ZigQua" title="Proceeds from sale of common stock">100,000</span>. Dr. Stephen Hake, a Trustee of the Stephen and Fredna Hake Trust DTD August 6, 2014, serves as a member of the Scientific Advisory Board of the Company and has a pre-established relationship with the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 100000 <p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z7aM5unajng8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 4. <span id="xdx_823_zUaGuRru96e3">RELATED PARTY TRANSACTIONS</span>.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As of June30, 2021 the Company is indebted to David Koos, the Company’s Chairman and Chief Executive Officer, in the amount of  $<span id="xdx_904_eus-gaap--ProceedsFromRelatedPartyDebt_c20200701__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DavidRKoosMember_pp0p0" title="Proceeds from related debt">1,879</span> ( “Koos Notes”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As of June 30,2021 the Company is indebted to BST Partners, Inc. , a company controlled by David Koos, in the amount of $<span id="xdx_909_eus-gaap--ProceedsFromRelatedPartyDebt_c20200701__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BSTPartnersMember_pp0p0" title="Proceeds from related debt">7,040</span> ( “BST Notes”)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Both the Koos Notes and BST Notes bear no interest and are due and payable upon demand of the Holder.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 provided to the Company by BST Partners, Inc. on a month to month basis free of charge. The property is utilized as office space. We believe that the foregoing properties are adequate to meet our current needs for office space. During the year ended June 30, 2021 the Company voluntarily paid $5,000 in rental expenses to BST Partner’s landlord on behalf of BST Partners, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"/> 1879 7040 <p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zCXuJBHJhjYj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 5. <span id="xdx_82B_zPrG9AdjJbCi">NOTES PAYABLE RELATED PARTY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfDebtTableTextBlock_zC77TAi00sk2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE RELATED PARTY (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_8B5_zlEK8rEXwo6c" style="display: none">Schedule of related party debt</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">David Koos</span></td><td style="width: 10%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--NotesPayableRelatedPartiesNoncurrent_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DavidRKoosMember_pp0p0" style="width: 18%; text-align: right" title="Notes Payable, Related Parties"><span style="font: 10pt Times New Roman, Times, Serif">1,879</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">BST Partners</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--NotesPayableRelatedPartiesNoncurrent_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BSTPartnersMember_pp0p0" style="text-align: right" title="Notes Payable, Related Parties"><span style="font: 10pt Times New Roman, Times, Serif">7,040</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Notes Payable, Related Parties</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--NotesPayableRelatedPartiesNoncurrent_c20210630_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Notes Payable, Related Parties"><span style="font: 10pt Times New Roman, Times, Serif">8,919</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2021 the Company is indebted to David R. Koos in the amount of $<span id="xdx_90F_eus-gaap--NotesPayableRelatedPartiesNoncurrent_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DavidRKoosMember_pp0p0" title="Notes Payable, Related Parties">1,879</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2021 the Company is indebted to BST Partners in the amount of $<span id="xdx_908_eus-gaap--NotesPayableRelatedPartiesNoncurrent_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BSTPartnersMember_pp0p0" title="Notes Payable, Related Parties">7,040</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">BST Partners is controlled by David R. Koos.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfDebtTableTextBlock_zC77TAi00sk2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE RELATED PARTY (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_8B5_zlEK8rEXwo6c" style="display: none">Schedule of related party debt</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">David Koos</span></td><td style="width: 10%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--NotesPayableRelatedPartiesNoncurrent_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DavidRKoosMember_pp0p0" style="width: 18%; text-align: right" title="Notes Payable, Related Parties"><span style="font: 10pt Times New Roman, Times, Serif">1,879</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">BST Partners</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--NotesPayableRelatedPartiesNoncurrent_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BSTPartnersMember_pp0p0" style="text-align: right" title="Notes Payable, Related Parties"><span style="font: 10pt Times New Roman, Times, Serif">7,040</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Notes Payable, Related Parties</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--NotesPayableRelatedPartiesNoncurrent_c20210630_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Notes Payable, Related Parties"><span style="font: 10pt Times New Roman, Times, Serif">8,919</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> 1879 7040 8919 1879 7040 <p id="xdx_800_eus-gaap--InvestmentHoldingsTextBlock_zKGYaMA4EuKh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 6. <span id="xdx_826_zmVTuKRfL429">INVESTMENT SECURITIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On March 11, 2021 the Company was paid <span id="xdx_90E_ecustom--NumberOfSharesIssuedForPropertyDividend_c20210301__20210311__dei--LegalEntityAxis__custom--OncologyPharmaIncMember_zXo1DdaG4fRi" title="Number of shares issued for property dividend">6,500</span> common shares of Oncology Pharma, Inc. pursuant to an agreement entered into by and between the Company and Oncology Pharma, Inc. whereby the Company granted Oncology Pharma, Inc. an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><span style="font: 10pt Times New Roman, Times, Serif">On June 30, 2021 the Company revalued <span id="xdx_900_ecustom--NumberOfSharesIssuedForPropertyDividend_c20200701__20210630__dei--LegalEntityAxis__custom--OncologyPharmaIncMember_pdd" title="Number of shares issued for property dividend">6,500</span> common shares of Oncology Pharma, Inc. at the closing price of the common shares on the OTC Pink market.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>As of June 30, 2021:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_ecustom--NumberOfSharesIssuedForPropertyDividend_c20200701__20210630__dei--LegalEntityAxis__custom--OncologyPharmaIncMember_zE0l2TI7AQBg" title="Number of shares issued for property dividend">6,500</span> Common shares of Oncolgy Pharma,Inc.<b/></span> </p> <table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--ScheduleOfCommonSharesTableTextBlock_zFPX2U1o4Y78" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INVESTMENT SECURITIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_8B5_zBTMD9Vstvd6" style="display: none">Schedule Of Common Shares</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Basis</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 19%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Fair Value</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 19%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total Unrealized Gains</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 19%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Net Unrealized Gain or (Loss) realized during the Quarter   ended June 30,2021</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td> <td id="xdx_98A_ecustom--InvestmentSecuritiesBasis_c20210630__dei--LegalEntityAxis__custom--OncologyPharmaIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Basis"><span style="font: 10pt Times New Roman, Times, Serif">177,450</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td> <td id="xdx_989_eus-gaap--AvailableForSaleSecurities_c20210630__dei--LegalEntityAxis__custom--OncologyPharmaIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Fair Value"><span style="font: 10pt Times New Roman, Times, Serif">185,250</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td> <td id="xdx_989_ecustom--InvestmentSecuritiesTotalUnrealizedLosses_c20210630__dei--LegalEntityAxis__custom--OncologyPharmaIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Total Unrealized Losses"><span style="font: 10pt Times New Roman, Times, Serif">7,800</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td> <td id="xdx_983_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20200701__20210630__dei--LegalEntityAxis__custom--OncologyPharmaIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Net Unrealized Gain or (Loss) realized"><span style="font: 10pt Times New Roman, Times, Serif">51,350</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"/> 6500 6500 6500 <table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--ScheduleOfCommonSharesTableTextBlock_zFPX2U1o4Y78" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INVESTMENT SECURITIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_8B5_zBTMD9Vstvd6" style="display: none">Schedule Of Common Shares</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Basis</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 19%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Fair Value</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 19%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total Unrealized Gains</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 19%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Net Unrealized Gain or (Loss) realized during the Quarter   ended June 30,2021</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td> <td id="xdx_98A_ecustom--InvestmentSecuritiesBasis_c20210630__dei--LegalEntityAxis__custom--OncologyPharmaIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Basis"><span style="font: 10pt Times New Roman, Times, Serif">177,450</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td> <td id="xdx_989_eus-gaap--AvailableForSaleSecurities_c20210630__dei--LegalEntityAxis__custom--OncologyPharmaIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Fair Value"><span style="font: 10pt Times New Roman, Times, Serif">185,250</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td> <td id="xdx_989_ecustom--InvestmentSecuritiesTotalUnrealizedLosses_c20210630__dei--LegalEntityAxis__custom--OncologyPharmaIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Total Unrealized Losses"><span style="font: 10pt Times New Roman, Times, Serif">7,800</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td> <td id="xdx_983_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20200701__20210630__dei--LegalEntityAxis__custom--OncologyPharmaIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Net Unrealized Gain or (Loss) realized"><span style="font: 10pt Times New Roman, Times, Serif">51,350</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> 177450 185250 7800 51350 <p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_z9vP48B23Luj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 7: <span id="xdx_82E_zzFALyxDpMgd">INCOME TAXES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>As of June 30, 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zCwTTQaX07D4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span id="xdx_8B1_zut6axDMKPSe" style="display: none">Schedule of Deferred Tax Assets</span></td><td> </td> <td colspan="3" id="xdx_496_20210630_zB5ND40J05Hd" style="text-align: right"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zmW8eAF2qok2" style="vertical-align: bottom"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred tax assets:</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzfzX_ziYdqz47Gi57" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Net operating tax carry forwards</span></td><td style="width: 10%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">12,645</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--DeferredIncomeTaxesAndOtherAssetsCurrent_iI_maDTAGzfzX_zegGlFyPDhfi" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzfzX_maDTANzFsA_zU3afdRF86I3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Gross deferred tax assets</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">12,645</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzFsA_zhP4UZiRfxT9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(12,645</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzFsA_zdH2J5tJPmUi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Net deferred tax assets</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2020 the Company has a Deferred Tax Asset of $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsGross_iI_c20210630_zV3QF0tB63h8" title="Deferred Tax Asset">12,645</span> completely attributable to net operating loss carry forwards of approximately $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_c20210630_zMwZbioOLDT7" title="Net operating loss carry forwards">60,219</span> generated during the calendar year ending December 31,2020   (which expire 20 years from the date the loss was incurred).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In addition, if as a result of a stock transfer or a reorganization, a corporation undergoes an “ownership change,” Code Section 382 limits the corporation’s right to use its NOLs each year thereafter to an annual percentage of the fair market value of the corporation at the time of the ownership change (the “Section 382 Limitation”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">A corporation is considered to undergo “an ownership change” if, as a result of changes in the stock ownership by “5-percent shareholders” or as a result of certain reorganizations, the percentage of the corporation’s stock owned by those 5-percent shareholders increases by more than 50 percentage points over the lowest percentage of stock owned by those shareholders at any time during the prior three-year testing period. Five-percent shareholders are persons who hold 5% or more of the stock of a corporation at any time during the testing period as well as certain groups of shareholders (based typically on whether they acquired their shares in a single offering or exchange transaction) who are not individually 5-percent shareholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As the Company will require cash infusions in order to implement its business plan, and as it is probable, although not guaranteed, that such funding needs may be met through the sale of equity securities to “5-percent shareholders”, the Company recognized a valuation allowance equal to the deferred Tax Asset and the Company recorded a valuation allowance reducing all deferred tax assets to 0.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Income tax is calculated at the <span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20200701__20210630_zeaT53UsHkTg" title="Federal Corporate Rate">21</span>% Federal Corporate Rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zCwTTQaX07D4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span id="xdx_8B1_zut6axDMKPSe" style="display: none">Schedule of Deferred Tax Assets</span></td><td> </td> <td colspan="3" id="xdx_496_20210630_zB5ND40J05Hd" style="text-align: right"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zmW8eAF2qok2" style="vertical-align: bottom"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred tax assets:</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzfzX_ziYdqz47Gi57" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Net operating tax carry forwards</span></td><td style="width: 10%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">12,645</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--DeferredIncomeTaxesAndOtherAssetsCurrent_iI_maDTAGzfzX_zegGlFyPDhfi" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzfzX_maDTANzFsA_zU3afdRF86I3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Gross deferred tax assets</span></td><td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">12,645</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzFsA_zhP4UZiRfxT9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(12,645</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzFsA_zdH2J5tJPmUi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Net deferred tax assets</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> 12645 0 12645 12645 0 12645 60219 0.21 <p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwU2lzpg5ax2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 8. <span id="xdx_828_z9WC2is5Ntlf">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The stockholders’ equity section of the Company contains the following class of capital stock as of June 30, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Common stock, $ <span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210630_zxqDSCtjuJH3" title="Common Stock par value">0.0001</span> par value; <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20210630_zDoMwKnKFGxb" title="Common Stock shares authorized">100,000,000</span> shares authorized: <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20210630_zUcoEoP7Q4sj" title="Common Stock shares issued"><span id="xdx_90F_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20210630_zzJmxyfXbk77" title="Common Stock shares outstanding">10,418,000</span></span>  shares issued and outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 0.0001 100000000 10418000 10418000 <p id="xdx_800_ecustom--StockTransactionsTextBlock_zT4dW6kKL4Wh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>NOTE 9. <span id="xdx_824_zRn9sUOM8Z2h">STOCK TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On July 7, 2020 the Company entered into an agreement with Dr. Stephen Hake whereby Dr. Hake agreed to serve as a member of the Company’s Scientific Advisory Board. Pursuant to the Agreement the Company is obligated to issue to Dr. Hake 40,000 of the Company’s common shares within 20 days of the execution of the Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On July 7, 2020 the Company entered into an agreement with Dr. Jason Garber whereby Dr. Garber agreed to serve as a member of the Company’s Scientific Advisory Board. Pursuant to the Agreement the Company is obligated to issue to Dr. Hake 25,000 of the Company’s common shares within 20 days of the execution of the Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On July 8, 2020 the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueOther_c20200701__20200708__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrStephenHakeMember_zbNyazIDlLel" title="Common stock issued">40,000</span> common shares to Dr. Stephen Hake</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On July 8, 2020 the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueOther_c20200701__20200708__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJasonGarberMember_zZ1XlmF8jF0b">25,000</span> common shares to Dr. Jason Garber.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On November 5th, 2020 SYBLEU INC. (the “Company”) sold one million of its common shares (“Shares”) for consideration of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20201101__20201105__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StephenHakeMember_pp0p0" title="Proceeds from sale of common stock">100,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 40000 25000 100000 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover - USD ($)
 12 Months Ended
Jun. 30, 2021
Sep. 20, 2021
Cover [Abstract]    
Document Type 10-K  
Amendment Flag false  
Document Annual Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2021  
Document Fiscal Period Focus FY  
Document Fiscal Year Focus 2021  
Current Fiscal Year End Date --06-30  
Entity File Number 333-248059  
Entity Registrant Name SYBLEU INC  
Entity Central Index Key 0001818674  
Entity Tax Identification Number 85-1412307  
Entity Incorporation, State or Country Code WY  
Entity Address, Address Line One 4700 Spring Street  
Entity Address, Address Line Two Suite 304  
Entity Address, City or Town La Mesa  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 91942  
City Area Code 619  
Local Phone Number 227-9192  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Current Reporting Status No  
Entity Interactive Data Current No  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Public Float   $ 0
Entity Common Stock, Shares Outstanding   10,418,000
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
BALANCE SHEETS - USD ($)
Jun. 30, 2021
Jun. 30, 2020
CURRENT ASSETS    
Cash $ 14,297 $ 5,050
Prepaid Expenses   3,500
     Total Current Assets 14,297 8,550
OTHER ASSETS    
Investment Securities 185,250 0
Total Other Assets 185,250 0
TOTAL ASSETS 199,547 8,550
Current Liabilities:    
Income Taxes Payable 21,394 0
Notes Payable, Related Party 8,919 11,329
Expenses Accrued but Unpaid 450 0
Total Current Liabilities 30,763 11,329
Total Liabilities 30,763 11,329
STOCKHOLDERS' EQUITY (DEFICIT)    
Common Stock ($.0001 par value) 100,000,000 shares authorized; par value $0.0001  9,353,000 shares issued and outstanding as of June 30,2020 and 10,418,000 shares issued and outstanding as of June 30,2021 1,042 935
Additional Paid in capital 100,049 145
Retained Earnings (Deficit ) 67,693 (3,859)
Total Stockholders' Equity (Deficit) 168,784 (2,779)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) $ 199,547 $ 8,550
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2021
Jun. 30, 2020
Statement of Financial Position [Abstract]    
Common stock, shares authorized 100,000,000 100,000,000
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares issued 10,418,000 9,353,000
Common stock, shares outstanding 10,418,000 9,353,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
STATEMENT OF OPERATIONS - USD ($)
 1 Months Ended 12 Months Ended
Jun. 30, 2020
Jun. 30, 2021
REVENUES    
License Fees $ 177,450
TOTAL REVENUES 177,450
Research and Development:    
Consulting Costs 2,250 26,311
Patent Application Costs 0 3,100
Total Research and Development 2,250 29,411
General and Administrative:    
Transfer Agency Fees 0 6,115
Other General and Administrative Expenses 609 1,898
Total General and Administrative 609 8,013
Consulting:    
Legal Fees 0 500
Accounting 0 11,880
Other Consulting 0 13,600
Website Development 1,000
Information Technology Consulting 0 23,900
Total Consulting 1,000 49,880
Rent 0 5,000
Total Costs and Expenses 3,859 92,304
OPERATING Income( LOSS) (3,859) 85,146
OTHER INCOME AND EXPENSES    
Unrealized Gain ( Loss) on Investment Securities 0 7,800
TOTAL OTHER INCOME ( EXPENSES) 0 7,800
NET INCOME ( LOSS) Before taxes (3,859) 92,946
Provision for Income Taxes 0 (21,394)
NET INCOME ( LOSS) $ (3,859) $ 71,552
BASIC AND FULLY DILUTED LOSS PER SHARE $ (0.00) $ 0.01
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING 9,353,000 10,054,932
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
STATEMENT OF SHAREHOLDERS EQUITY (DEFICIT) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Jun. 12, 2020
Balance at beginning, shares at Jun. 12, 2020      
Common shares issued to Parent June 13,2020 $ 935 145   1,080
Common shares issued toParent June 13,2020, share 9,353,000      
Net Loss     (3,859) (3,859)
Ending balance, value at Jun. 30, 2020 $ 935 145 (3,859) (2,779)
Balance at ending, shares at Jun. 30, 2020 9,353,000      
Common shares issued for non employee services July 8,2020 $ 7 4   11
Stock Issued During Period, Shares, Issued for Services 65,000      
Net Loss (21,896) (21,896)
Ending balance, value at Sep. 30, 2020 $ 942 149 (25,755) (24,664)
Balance at ending, shares at Sep. 30, 2020 9,418,000      
Common Shares issued for cash   November 9,2020 $ 100 99,900   100,000
Stock Issued During Period, Shares, New Issues 1,000,000      
Net Loss (34,463) (34,463)
Ending balance, value at Dec. 31, 2020 $ 1,042 100,049 (60,218) 40,873
Balance at ending, shares at Dec. 31, 2020 10,418,000      
Net Loss 89,716 89,716
Ending balance, value at Mar. 31, 2021 $ 1,042 100,049 29,498 130,589
Balance at ending, shares at Mar. 31, 2021 10,418,000      
Net Loss 38,195 38,195
Ending balance, value at Jun. 30, 2021 $ 1,042 $ 100,049 $ 67,693 $ 168,784
Balance at ending, shares at Jun. 30, 2021 10,418,000      
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
STATEMENT OF CASH FLOWS - USD ($)
 1 Months Ended 12 Months Ended
Jun. 30, 2020
Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES    
Net Income (Loss) $ (3,859) $ 71,552
Adjustments to reconcile net Income (loss) to net cash    
Common Stock Issued for payment of expenses 1,080 11
Changes in Operating Assets and Liabilities    
(Increase) Decrease in Prepaid Expenses (3,500) 3,500
Increase (Decrease) in Accrued Expenses 0 450
(Increase) Decrease in Securities accepted as  Payment 0 (177,450)
Increase (Decrease) in Income Tax Payable 0 21,394
Unrealized Loss ( Gain) in Investment Securities 0 (7,800)
Net Cash provided by (used) in Operating Activities (6,279) (88,343)
CASH FLOWS FROM FINANCING ACTIVITIES    
Increase ( Decrease)   in Notes Payable, Related Parties 11,329 (2,410)
Common Stock issued for Cash 0 100,000
Net Cash provided by (used) in Financing Activities 11,329 97,590
Net Increase (Decrease) in Cash 5,050 9,247
Cash at Beginning of Period 0 5,050
Cash at End of Period 5,050 14,297
Supplemental Cash Flow Information:    
Interest Paid 0 0
Income Taxes Paid $ 0 $ 0
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

SYBLEU INC. (“Company”) was organized June 12, 2020 under the laws of the State of Wyoming.

  

The Company intends to engage primarily in the development of regenerative medical applications up to the point of successful completion of Phase I and or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The primary factor to be considered by us in arriving at a decision to advance an application further to Phase III clinical trials would be a greater than anticipated indication of efficacy seen in Phase I trials.

 

A. BASIS OF ACCOUNTING

 

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a June 30 year-end.

 

B. USE OF ESTIMATES

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

C. CASH EQUIVALENTS

 

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

   

D. FAIR VALUE OF FINANCIAL INSTRUMENTS

 

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

 

Level 1:  Quoted prices in active markets for identical assets or liabilities

 

Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

 

Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

E. RESEARCH AND DEVELOPMENT COSTS

 

Research and development expenses relate primarily to the cost of discovery and research programs. Research and development costs are charged to expense as incurred. Research and development expenses consist mainly of evaluating potential Contract Research Organizations and filing of a provisional patent application.

 


F. STOCK BASED COMPENSATION

 

Stock issued for Employee Compensation 

 

Stock based compensation to employees is accounted for at the award’s fair value at grant, less the amount (if any) paid by the award recipient.

 

During the year ended June 30,2021 no stock was issued for employee compensation.

 

Stock issued for Non-Employee Services

 

Stock Based compensation to non-employees is accounted for in accordance with ASC 505-50. ASC 505-50 requires entities to account for non-employee equity transactions based on either the fair value of the services received or the fair value of the equity instrument issued utilizing whichever measurement is most reliable. Stock issued for compensation to non employees during the quarter ended September 30, 2020 was accounted for at the fair value of the equity instruments issued as there were no dollar amounts billed to the Company for services rendered by the non employees.

 

In determining the Fair Value of shares issued as compensation, the Company took into account factors including the financial condition of the Company at the time of grant, the Company’s lack of profitability, the lack of cash sales of the Company’s stock, and the Company’s negative working capital as of the time of grant.

 

Pursuant to ASC 505-50-30-11505-50-30-11 an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date:

 

i.   The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and

 

ii.  

The date at which the counterparty’s performance is complete.

 

 

The Company has assessed that the date of issuance of the stock grant constituted commitment for performance therefore stock grants to non employees issued during the period were measured as of the issue date. The following summarizes the Company’s issuance of stock for non employee services for the quarter ended September 30, 2020:

 

      
Balance July 1, 2020   
Unvested Shares    0 
Vested Shares    0 
Total July 1, 2020    0 
Shares Issued Vested    65,000 
Balance September 30, 2020    65,000 


In determining Fair Value for shares issued to nonemployees an asset based valuation method was utilized , specifically Enterprise Value(Assets Less Cash and Cash Equivalents plus Fair Value of Debt) less Fair Value of Debt. The following inputs were utilized.

 

65,000 of the Common Shares of the Company issued on July 8, 2020:

 

     
Fair Value of Intellectual Property as of July 8, 2020   1,545 
Notes Payable as of July 8, 2020   13,329 
Enterprise Value as of July 8, 2020   14,874 
Less: Total Debt   (13,329)
Portion of Enterprise Value available to Common Shareholders   1,545 
Per Share Portion of Enterprise Value available to Common Shareholders  $0.000164 

 

During the quarters ended December 31,2020, March 31, 2021 and June 30, 2020 no stock was issued for non- employee compensation.

G. INCOME TAXES

 

The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

 

The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2021 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

 

The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.

 

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

 

H.  BASIC EARNINGS (LOSS) PER SHARE

 

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.

 

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. There were no Common Stock Equivalents as of June 30, 2021.

 
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
RECENT ACCOUNTING PRONOUNCEMENTS
 12 Months Ended
Jun. 30, 2021
Accounting Changes and Error Corrections [Abstract]  
RECENT ACCOUNTING PRONOUNCEMENTS


NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS 

 

The Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification.

 

The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The Company has adopted the provisions of this ASU effective the fiscal year ended 2020. This guidance did not have a material impact on the Company’s Financial Statements.

 

On February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (Topic 842). The ASU requires organizations that lease assets, referred to as "lessees," to recognize on the consolidated statement of financial position the rights and obligations created by those leases. The ASU also requires disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the consolidated financial statements. The ASU on leases became effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company has not adopted the provisions of this ASU. This guidance is not expected to have a material impact on the Company’s financial statements.

 

In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. This ASU is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with the accounting for employee share-based compensation. This ASU is effective for annual periods beginning after December 15, 2018 and interim periods within those annual periods, with early adoption permitted. The Company has not adopted the provisions of this ASU. This guidance is not expected to have a material impact on the Company’s financial statements.

 
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
GOING CONCERN
 12 Months Ended
Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GOING CONCERN

NOTE 3. GOING CONCERN

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has generated minimal earnings during the period from June 12, 2020 (inception) through June 30,2021. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings.

 

On November 5th, 2020 the Company sold one million of its common shares (“Shares”) to The Stephen and Fredna Hake Trust DTD August 6, 2014 for consideration of $100,000. Dr. Stephen Hake, a Trustee of the Stephen and Fredna Hake Trust DTD August 6, 2014, serves as a member of the Scientific Advisory Board of the Company and has a pre-established relationship with the Company.

 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
RELATED PARTY TRANSACTIONS
 12 Months Ended
Jun. 30, 2021
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 4. RELATED PARTY TRANSACTIONS.

 

As of June30, 2021 the Company is indebted to David Koos, the Company’s Chairman and Chief Executive Officer, in the amount of  $1,879 ( “Koos Notes”).

 

As of June 30,2021 the Company is indebted to BST Partners, Inc. , a company controlled by David Koos, in the amount of $7,040 ( “BST Notes”)

 

Both the Koos Notes and BST Notes bear no interest and are due and payable upon demand of the Holder.

 

The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 provided to the Company by BST Partners, Inc. on a month to month basis free of charge. The property is utilized as office space. We believe that the foregoing properties are adequate to meet our current needs for office space. During the year ended June 30, 2021 the Company voluntarily paid $5,000 in rental expenses to BST Partner’s landlord on behalf of BST Partners, Inc.

 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
NOTES PAYABLE RELATED PARTY
 12 Months Ended
Jun. 30, 2021
Debt Disclosure [Abstract]  
NOTES PAYABLE RELATED PARTY

NOTE 5. NOTES PAYABLE RELATED PARTY

 

     
David Koos   1,879 
BST Partners   7,040 
Notes Payable, Related Parties  $8,919 

 

As of June 30, 2021 the Company is indebted to David R. Koos in the amount of $1,879.

 

As of June 30, 2021 the Company is indebted to BST Partners in the amount of $7,040.

 

BST Partners is controlled by David R. Koos.

 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
INVESTMENT SECURITIES
 12 Months Ended
Jun. 30, 2021
Schedule of Investments [Abstract]  
INVESTMENT SECURITIES

NOTE 6. INVESTMENT SECURITIES

 

On March 11, 2021 the Company was paid 6,500 common shares of Oncology Pharma, Inc. pursuant to an agreement entered into by and between the Company and Oncology Pharma, Inc. whereby the Company granted Oncology Pharma, Inc. an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by the Company.

 

On June 30, 2021 the Company revalued 6,500 common shares of Oncology Pharma, Inc. at the closing price of the common shares on the OTC Pink market.

As of June 30, 2021:

6,500 Common shares of Oncolgy Pharma,Inc. 

                           
             
  Basis       Fair Value       Total Unrealized Gains       Net Unrealized Gain or (Loss) realized during the Quarter   ended June 30,2021  
$ 177,450     $ 185,250     $ 7,800     $ 51,350  
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
INCOME TAXES
 12 Months Ended
Jun. 30, 2021
Income Tax Disclosure [Abstract]  
INCOME TAXES

NOTE 7: INCOME TAXES

As of June 30, 2021

 

   
Deferred tax assets:   
Net operating tax carry forwards  $12,645 
Other   0 
Gross deferred tax assets   12,645 
Valuation allowance   (12,645)
Net deferred tax assets  $0 

 

As of June 30, 2020 the Company has a Deferred Tax Asset of $12,645 completely attributable to net operating loss carry forwards of approximately $60,219 generated during the calendar year ending December 31,2020   (which expire 20 years from the date the loss was incurred).

 

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain.

 

In addition, if as a result of a stock transfer or a reorganization, a corporation undergoes an “ownership change,” Code Section 382 limits the corporation’s right to use its NOLs each year thereafter to an annual percentage of the fair market value of the corporation at the time of the ownership change (the “Section 382 Limitation”).

 

A corporation is considered to undergo “an ownership change” if, as a result of changes in the stock ownership by “5-percent shareholders” or as a result of certain reorganizations, the percentage of the corporation’s stock owned by those 5-percent shareholders increases by more than 50 percentage points over the lowest percentage of stock owned by those shareholders at any time during the prior three-year testing period. Five-percent shareholders are persons who hold 5% or more of the stock of a corporation at any time during the testing period as well as certain groups of shareholders (based typically on whether they acquired their shares in a single offering or exchange transaction) who are not individually 5-percent shareholders.

 

As the Company will require cash infusions in order to implement its business plan, and as it is probable, although not guaranteed, that such funding needs may be met through the sale of equity securities to “5-percent shareholders”, the Company recognized a valuation allowance equal to the deferred Tax Asset and the Company recorded a valuation allowance reducing all deferred tax assets to 0.

 

Income tax is calculated at the 21% Federal Corporate Rate.

 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS’ EQUITY
 12 Months Ended
Jun. 30, 2021
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 8. STOCKHOLDERS’ EQUITY

 

The stockholders’ equity section of the Company contains the following class of capital stock as of June 30, 2021:

 

Common stock, $ 0.0001 par value; 100,000,000 shares authorized: 10,418,000  shares issued and outstanding.

 

With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).

 

On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation.

 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
STOCK TRANSACTIONS
 12 Months Ended
Jun. 30, 2021
Stock Transactions  
STOCK TRANSACTIONS

NOTE 9. STOCK TRANSACTIONS

 

On July 7, 2020 the Company entered into an agreement with Dr. Stephen Hake whereby Dr. Hake agreed to serve as a member of the Company’s Scientific Advisory Board. Pursuant to the Agreement the Company is obligated to issue to Dr. Hake 40,000 of the Company’s common shares within 20 days of the execution of the Agreement.

 

On July 7, 2020 the Company entered into an agreement with Dr. Jason Garber whereby Dr. Garber agreed to serve as a member of the Company’s Scientific Advisory Board. Pursuant to the Agreement the Company is obligated to issue to Dr. Hake 25,000 of the Company’s common shares within 20 days of the execution of the Agreement.

 

On July 8, 2020 the Company issued 40,000 common shares to Dr. Stephen Hake

 

On July 8, 2020 the Company issued 25,000 common shares to Dr. Jason Garber.

 

On November 5th, 2020 SYBLEU INC. (the “Company”) sold one million of its common shares (“Shares”) for consideration of $100,000.

 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF ACCOUNTING

A. BASIS OF ACCOUNTING

 

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a June 30 year-end.

 
USE OF ESTIMATES

B. USE OF ESTIMATES

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 
CASH EQUIVALENTS

C. CASH EQUIVALENTS

 

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

   
FAIR VALUE OF FINANCIAL INSTRUMENTS

D. FAIR VALUE OF FINANCIAL INSTRUMENTS

 

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

 

Level 1:  Quoted prices in active markets for identical assets or liabilities

 

Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

 

Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 
RESEARCH AND DEVELOPMENT COSTS

E. RESEARCH AND DEVELOPMENT COSTS

 

Research and development expenses relate primarily to the cost of discovery and research programs. Research and development costs are charged to expense as incurred. Research and development expenses consist mainly of evaluating potential Contract Research Organizations and filing of a provisional patent application.

 
STOCK BASED COMPENSATION


F. STOCK BASED COMPENSATION

 

Stock issued for Employee Compensation 

 

Stock based compensation to employees is accounted for at the award’s fair value at grant, less the amount (if any) paid by the award recipient.

 

During the year ended June 30,2021 no stock was issued for employee compensation.

 

Stock issued for Non-Employee Services

 

Stock Based compensation to non-employees is accounted for in accordance with ASC 505-50. ASC 505-50 requires entities to account for non-employee equity transactions based on either the fair value of the services received or the fair value of the equity instrument issued utilizing whichever measurement is most reliable. Stock issued for compensation to non employees during the quarter ended September 30, 2020 was accounted for at the fair value of the equity instruments issued as there were no dollar amounts billed to the Company for services rendered by the non employees.

 

In determining the Fair Value of shares issued as compensation, the Company took into account factors including the financial condition of the Company at the time of grant, the Company’s lack of profitability, the lack of cash sales of the Company’s stock, and the Company’s negative working capital as of the time of grant.

 

Pursuant to ASC 505-50-30-11505-50-30-11 an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date:

 

i.   The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and

 

ii.  

The date at which the counterparty’s performance is complete.

 

 

The Company has assessed that the date of issuance of the stock grant constituted commitment for performance therefore stock grants to non employees issued during the period were measured as of the issue date. The following summarizes the Company’s issuance of stock for non employee services for the quarter ended September 30, 2020:

 

      
Balance July 1, 2020   
Unvested Shares    0 
Vested Shares    0 
Total July 1, 2020    0 
Shares Issued Vested    65,000 
Balance September 30, 2020    65,000 


In determining Fair Value for shares issued to nonemployees an asset based valuation method was utilized , specifically Enterprise Value(Assets Less Cash and Cash Equivalents plus Fair Value of Debt) less Fair Value of Debt. The following inputs were utilized.

 

65,000 of the Common Shares of the Company issued on July 8, 2020:

 

     
Fair Value of Intellectual Property as of July 8, 2020   1,545 
Notes Payable as of July 8, 2020   13,329 
Enterprise Value as of July 8, 2020   14,874 
Less: Total Debt   (13,329)
Portion of Enterprise Value available to Common Shareholders   1,545 
Per Share Portion of Enterprise Value available to Common Shareholders  $0.000164 

 

During the quarters ended December 31,2020, March 31, 2021 and June 30, 2020 no stock was issued for non- employee compensation.
INCOME TAXES

G. INCOME TAXES

 

The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

 

The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2021 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

 

The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.

 

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

 
BASIC EARNINGS (LOSS) PER SHARE

H.  BASIC EARNINGS (LOSS) PER SHARE

 

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.

 

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. There were no Common Stock Equivalents as of June 30, 2021.

 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule Of Issuance Of Stock For Non employee Services
      
Balance July 1, 2020   
Unvested Shares    0 
Vested Shares    0 
Total July 1, 2020    0 
Shares Issued Vested    65,000 
Balance September 30, 2020    65,000 
Schedule Of Valuation Method Of Fair Value Of Unvested Shares
     
Fair Value of Intellectual Property as of July 8, 2020   1,545 
Notes Payable as of July 8, 2020   13,329 
Enterprise Value as of July 8, 2020   14,874 
Less: Total Debt   (13,329)
Portion of Enterprise Value available to Common Shareholders   1,545 
Per Share Portion of Enterprise Value available to Common Shareholders  $0.000164 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
NOTES PAYABLE RELATED PARTY (Tables)
 12 Months Ended
Jun. 30, 2021
Debt Disclosure [Abstract]  
Schedule of related party debt
     
David Koos   1,879 
BST Partners   7,040 
Notes Payable, Related Parties  $8,919 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
INVESTMENT SECURITIES (Tables)
 12 Months Ended
Jun. 30, 2021
Schedule of Investments [Abstract]  
Schedule Of Common Shares
                           
             
  Basis       Fair Value       Total Unrealized Gains       Net Unrealized Gain or (Loss) realized during the Quarter   ended June 30,2021  
$ 177,450     $ 185,250     $ 7,800     $ 51,350  
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
INCOME TAXES (Tables)
 12 Months Ended
Jun. 30, 2021
Income Tax Disclosure [Abstract]  
Schedule of Deferred Tax Assets
   
Deferred tax assets:   
Net operating tax carry forwards  $12,645 
Other   0 
Gross deferred tax assets   12,645 
Valuation allowance   (12,645)
Net deferred tax assets  $0 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares
 3 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Unvested Shares at beginning   0
Vested Shares   0
Total Shares Issued For Non Employee Services 0  
Shares issued vested 65,000  
Ending balnce, shares 65,000  
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)
Jul. 08, 2021
USD ($)
$ / shares
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Fair Value of Intellectual Property as of July 8, 2020 $ 1,545
Notes Payable as of July 8, 2020 13,329
Enterprise Value as of July 8, 2020 14,874
Less: Total Debt (13,329)
Portion of Enterprise Value available to Common Shareholders $ 1,545
Per Share Portion of Enterprise Value available to Common Shareholders | $ / shares $ 0.000164
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
GOING CONCERN (Details Narrative)
Nov. 05, 2020
USD ($)
Stephen Hake [Member]  
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]  
Proceeds from sale of common stock $ 100,000
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
RELATED PARTY TRANSACTIONS (Details Narrative)
 12 Months Ended
Jun. 30, 2021
USD ($)
David R Koos [Member]  
Related Party Transaction [Line Items]  
Proceeds from related debt $ 1,879
B S T Partners [Member]  
Related Party Transaction [Line Items]  
Proceeds from related debt $ 7,040
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
NOTES PAYABLE RELATED PARTY (Details)
Jun. 30, 2021
USD ($)
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]  
Notes Payable, Related Parties $ 8,919
David R Koos [Member]  
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]  
Notes Payable, Related Parties 1,879
B S T Partners [Member]  
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]  
Notes Payable, Related Parties $ 7,040
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
NOTES PAYABLE RELATED PARTY (Details Narrative)
Jun. 30, 2021
USD ($)
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]  
Notes Payable, Related Parties $ 8,919
David R Koos [Member]  
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]  
Notes Payable, Related Parties 1,879
B S T Partners [Member]  
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]  
Notes Payable, Related Parties $ 7,040
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
INVESTMENT SECURITIES (Details) - Oncology Pharma Inc [Member]
 12 Months Ended
Jun. 30, 2021
USD ($)
Schedule of Investments [Line Items]  
Investment Securities, Basis $ 177,450
Investment Securities, Fair Value 185,250
Investment Securities, Total Unrealized Losses 7,800
Investment Securities, Net Unrealized Gain or (Loss) realized $ 51,350
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
INVESTMENT SECURITIES (Details Narrative) - shares
 12 Months Ended
Mar. 11, 2021
Jun. 30, 2021
Oncology Pharma Inc [Member]    
Schedule of Investments [Line Items]    
Number of shares issued for property dividend 6,500 6,500
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
INCOME TAXES (Details)
Jun. 30, 2021
USD ($)
Deferred tax assets:  
Net operating tax carry forwards $ 12,645
Other 0
Gross deferred tax assets 12,645
Valuation allowance (12,645)
Net deferred tax assets $ 0
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
INCOME TAXES (Details Narrative)
 12 Months Ended
Jun. 30, 2021
USD ($)
Income Tax Disclosure [Abstract]  
Deferred Tax Asset $ 12,645
Net operating loss carry forwards $ 60,219
Federal Corporate Rate 21.00%
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS’ EQUITY (Details Narrative) - $ / shares
Jun. 30, 2021
Jun. 30, 2020
Equity [Abstract]    
Common Stock par value $ 0.0001 $ 0.0001
Common Stock shares authorized 100,000,000 100,000,000
Common Stock shares issued 10,418,000 9,353,000
Common Stock shares outstanding 10,418,000 9,353,000
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
STOCK TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended
Nov. 05, 2020
Jul. 08, 2020
Jun. 30, 2020
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]      
Common stock issued     $ 1,080
Dr Stephen Hake [Member]      
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]      
Common stock issued   $ 40,000  
Dr Jason Garber [Member]      
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]      
Common stock issued   $ 25,000  
Stephen Hake [Member]      
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]      
Proceeds from sale of common stock $ 100,000    
EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 45 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 57 210 1 false 9 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://sybleuinc.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - BALANCE SHEETS Sheet http://sybleuinc.com/role/BalanceSheets BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - BALANCE SHEETS (Parenthetical) Sheet http://sybleuinc.com/role/BalanceSheetsParenthetical BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - STATEMENT OF OPERATIONS Sheet http://sybleuinc.com/role/StatementOfOperations STATEMENT OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - STATEMENT OF SHAREHOLDERS EQUITY (DEFICIT) Sheet http://sybleuinc.com/role/StatementOfShareholdersEquityDeficit STATEMENT OF SHAREHOLDERS EQUITY (DEFICIT) Statements 5 false false R6.htm 00000006 - Statement - STATEMENT OF CASH FLOWS Sheet http://sybleuinc.com/role/StatementOfCashFlows STATEMENT OF CASH FLOWS Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 00000008 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet http://sybleuinc.com/role/RecentAccountingPronouncements RECENT ACCOUNTING PRONOUNCEMENTS Notes 8 false false R9.htm 00000009 - Disclosure - GOING CONCERN Sheet http://sybleuinc.com/role/GoingConcern GOING CONCERN Notes 9 false false R10.htm 00000010 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://sybleuinc.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 10 false false R11.htm 00000011 - Disclosure - NOTES PAYABLE RELATED PARTY Notes http://sybleuinc.com/role/NotesPayableRelatedParty NOTES PAYABLE RELATED PARTY Notes 11 false false R12.htm 00000012 - Disclosure - INVESTMENT SECURITIES Sheet http://sybleuinc.com/role/InvestmentSecurities INVESTMENT SECURITIES Notes 12 false false R13.htm 00000013 - Disclosure - INCOME TAXES Sheet http://sybleuinc.com/role/IncomeTaxes INCOME TAXES Notes 13 false false R14.htm 00000014 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://sybleuinc.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 14 false false R15.htm 00000015 - Disclosure - STOCK TRANSACTIONS Sheet http://sybleuinc.com/role/StockTransactions STOCK TRANSACTIONS Notes 15 false false R16.htm 00000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 16 false false R17.htm 00000017 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - NOTES PAYABLE RELATED PARTY (Tables) Notes http://sybleuinc.com/role/NotesPayableRelatedPartyTables NOTES PAYABLE RELATED PARTY (Tables) Tables http://sybleuinc.com/role/NotesPayableRelatedParty 18 false false R19.htm 00000019 - Disclosure - INVESTMENT SECURITIES (Tables) Sheet http://sybleuinc.com/role/InvestmentSecuritiesTables INVESTMENT SECURITIES (Tables) Tables http://sybleuinc.com/role/InvestmentSecurities 19 false false R20.htm 00000020 - Disclosure - INCOME TAXES (Tables) Sheet http://sybleuinc.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://sybleuinc.com/role/IncomeTaxes 20 false false R21.htm 00000021 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 21 false false R22.htm 00000022 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) Sheet http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) Details http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 22 false false R23.htm 00000023 - Disclosure - GOING CONCERN (Details Narrative) Sheet http://sybleuinc.com/role/GoingConcernDetailsNarrative GOING CONCERN (Details Narrative) Details http://sybleuinc.com/role/GoingConcern 23 false false R24.htm 00000024 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://sybleuinc.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://sybleuinc.com/role/RelatedPartyTransactions 24 false false R25.htm 00000025 - Disclosure - NOTES PAYABLE RELATED PARTY (Details) Notes http://sybleuinc.com/role/NotesPayableRelatedPartyDetails NOTES PAYABLE RELATED PARTY (Details) Details http://sybleuinc.com/role/NotesPayableRelatedPartyTables 25 false false R26.htm 00000026 - Disclosure - NOTES PAYABLE RELATED PARTY (Details Narrative) Notes http://sybleuinc.com/role/NotesPayableRelatedPartyDetailsNarrative NOTES PAYABLE RELATED PARTY (Details Narrative) Details http://sybleuinc.com/role/NotesPayableRelatedPartyTables 26 false false R27.htm 00000027 - Disclosure - INVESTMENT SECURITIES (Details) Sheet http://sybleuinc.com/role/InvestmentSecuritiesDetails INVESTMENT SECURITIES (Details) Details http://sybleuinc.com/role/InvestmentSecuritiesTables 27 false false R28.htm 00000028 - Disclosure - INVESTMENT SECURITIES (Details Narrative) Sheet http://sybleuinc.com/role/InvestmentSecuritiesDetailsNarrative INVESTMENT SECURITIES (Details Narrative) Details http://sybleuinc.com/role/InvestmentSecuritiesTables 28 false false R29.htm 00000029 - Disclosure - INCOME TAXES (Details) Sheet http://sybleuinc.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://sybleuinc.com/role/IncomeTaxesTables 29 false false R30.htm 00000030 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://sybleuinc.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://sybleuinc.com/role/IncomeTaxesTables 30 false false R31.htm 00000031 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://sybleuinc.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://sybleuinc.com/role/StockholdersEquity 31 false false R32.htm 00000032 - Disclosure - STOCK TRANSACTIONS (Details Narrative) Sheet http://sybleuinc.com/role/StockTransactionsDetailsNarrative STOCK TRANSACTIONS (Details Narrative) Details http://sybleuinc.com/role/StockTransactions 32 false false All Reports Book All Reports sybleu063021form10k.htm cik0001818674-20210630.xsd cik0001818674-20210630_cal.xml cik0001818674-20210630_def.xml cik0001818674-20210630_lab.xml cik0001818674-20210630_pre.xml ex31_1.htm ex31_2.htm ex32_1.htm ex32_2.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 http://fasb.org/srt/2021-01-31 true true JSON 50 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sybleu063021form10k.htm": { "axisCustom": 0, "axisStandard": 3, "contextCount": 57, "dts": { "calculationLink": { "local": [ "cik0001818674-20210630_cal.xml" ] }, "definitionLink": { "local": [ "cik0001818674-20210630_def.xml" ] }, "inline": { "local": [ "sybleu063021form10k.htm" ] }, "labelLink": { "local": [ "cik0001818674-20210630_lab.xml" ] }, "presentationLink": { "local": [ "cik0001818674-20210630_pre.xml" ] }, "schema": { "local": [ "cik0001818674-20210630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 226, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 14, "http://sybleuinc.com/20210630": 2, "http://xbrl.sec.gov/dei/2021": 5, "total": 21 }, "keyCustom": 23, "keyStandard": 187, "memberCustom": 6, "memberStandard": 3, "nsprefix": "CIK0001818674", "nsuri": "http://sybleuinc.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://sybleuinc.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://sybleuinc.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - NOTES PAYABLE RELATED PARTY", "role": "http://sybleuinc.com/role/NotesPayableRelatedParty", "shortName": "NOTES PAYABLE RELATED PARTY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentHoldingsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - INVESTMENT SECURITIES", "role": "http://sybleuinc.com/role/InvestmentSecurities", "shortName": "INVESTMENT SECURITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentHoldingsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - INCOME TAXES", "role": "http://sybleuinc.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "role": "http://sybleuinc.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "CIK0001818674:StockTransactionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - STOCK TRANSACTIONS", "role": "http://sybleuinc.com/role/StockTransactions", "shortName": "STOCK TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "CIK0001818674:StockTransactionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "CIK0001818674:ScheduleOfIssuanceOfStockForNonemployeeServices", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "CIK0001818674:ScheduleOfIssuanceOfStockForNonemployeeServices", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - NOTES PAYABLE RELATED PARTY (Tables)", "role": "http://sybleuinc.com/role/NotesPayableRelatedPartyTables", "shortName": "NOTES PAYABLE RELATED PARTY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentHoldingsTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "CIK0001818674:ScheduleOfCommonSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - INVESTMENT SECURITIES (Tables)", "role": "http://sybleuinc.com/role/InvestmentSecuritiesTables", "shortName": "INVESTMENT SECURITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentHoldingsTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "CIK0001818674:ScheduleOfCommonSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - BALANCE SHEETS", "role": "http://sybleuinc.com/role/BalanceSheets", "shortName": "BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - INCOME TAXES (Tables)", "role": "http://sybleuinc.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "CIK0001818674:ScheduleOfIssuanceOfStockForNonemployeeServices", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "AsOf2020-06-30", "decimals": "INF", "first": true, "lang": null, "name": "CIK0001818674:UnvestedSharesForNonEmployeeServices", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "role": "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "CIK0001818674:ScheduleOfIssuanceOfStockForNonemployeeServices", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "AsOf2020-06-30", "decimals": "INF", "first": true, "lang": null, "name": "CIK0001818674:UnvestedSharesForNonEmployeeServices", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "CIK0001818674:ScheduleOfValuationMethodOfFairValueOfUnvestedShares", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "AsOf2021-07-08", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)", "role": "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "CIK0001818674:ScheduleOfValuationMethodOfFairValueOfUnvestedShares", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "AsOf2021-07-08", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-11-012020-11-05_custom_StephenHakeMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - GOING CONCERN (Details Narrative)", "role": "http://sybleuinc.com/role/GoingConcernDetailsNarrative", "shortName": "GOING CONCERN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R24": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-012021-06-30_custom_DavidRKoosMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromRelatedPartyDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "role": "http://sybleuinc.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-012021-06-30_custom_DavidRKoosMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromRelatedPartyDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesNoncurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - NOTES PAYABLE RELATED PARTY (Details)", "role": "http://sybleuinc.com/role/NotesPayableRelatedPartyDetails", "shortName": "NOTES PAYABLE RELATED PARTY (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesNoncurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - NOTES PAYABLE RELATED PARTY (Details Narrative)", "role": "http://sybleuinc.com/role/NotesPayableRelatedPartyDetailsNarrative", "shortName": "NOTES PAYABLE RELATED PARTY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "CIK0001818674:ScheduleOfCommonSharesTableTextBlock", "us-gaap:InvestmentHoldingsTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "AsOf2021-06-30_custom_OncologyPharmaIncMember", "decimals": "0", "first": true, "lang": null, "name": "CIK0001818674:InvestmentSecuritiesBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - INVESTMENT SECURITIES (Details)", "role": "http://sybleuinc.com/role/InvestmentSecuritiesDetails", "shortName": "INVESTMENT SECURITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "CIK0001818674:ScheduleOfCommonSharesTableTextBlock", "us-gaap:InvestmentHoldingsTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "AsOf2021-06-30_custom_OncologyPharmaIncMember", "decimals": "0", "first": true, "lang": null, "name": "CIK0001818674:InvestmentSecuritiesBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:InvestmentHoldingsTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2021-03-012021-03-11_custom_OncologyPharmaIncMember", "decimals": "INF", "first": true, "lang": null, "name": "CIK0001818674:NumberOfSharesIssuedForPropertyDividend", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - INVESTMENT SECURITIES (Details Narrative)", "role": "http://sybleuinc.com/role/InvestmentSecuritiesDetailsNarrative", "shortName": "INVESTMENT SECURITIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:InvestmentHoldingsTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2021-03-012021-03-11_custom_OncologyPharmaIncMember", "decimals": "INF", "first": true, "lang": null, "name": "CIK0001818674:NumberOfSharesIssuedForPropertyDividend", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - INCOME TAXES (Details)", "role": "http://sybleuinc.com/role/IncomeTaxesDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - BALANCE SHEETS (Parenthetical)", "role": "http://sybleuinc.com/role/BalanceSheetsParenthetical", "shortName": "BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - INCOME TAXES (Details Narrative)", "role": "http://sybleuinc.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "role": "http://sybleuinc.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-06-132020-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueOther", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - STOCK TRANSACTIONS (Details Narrative)", "role": "http://sybleuinc.com/role/StockTransactionsDetailsNarrative", "shortName": "STOCK TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "CIK0001818674:StockTransactionsTextBlock", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-012020-07-08_custom_DrStephenHakeMember", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueOther", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "CIK0001818674:LicenseFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - STATEMENT OF OPERATIONS", "role": "http://sybleuinc.com/role/StatementOfOperations", "shortName": "STATEMENT OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "CIK0001818674:LicenseFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-06-132020-06-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueOther", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - STATEMENT OF SHAREHOLDERS EQUITY (DEFICIT)", "role": "http://sybleuinc.com/role/StatementOfShareholdersEquityDeficit", "shortName": "STATEMENT OF SHAREHOLDERS EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-06-132020-06-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueOther", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-06-132020-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - STATEMENT OF CASH FLOWS", "role": "http://sybleuinc.com/role/StatementOfCashFlows", "shortName": "STATEMENT OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-06-132020-06-30", "decimals": "0", "lang": null, "name": "CIK0001818674:CommonStockIssuedForPaymentOfExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS", "role": "http://sybleuinc.com/role/RecentAccountingPronouncements", "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - GOING CONCERN", "role": "http://sybleuinc.com/role/GoingConcern", "shortName": "GOING CONCERN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybleu063021form10k.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 9, "tag": { "CIK0001818674_AccountingExpenses": { "auth_ref": [], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "CIK0001818674_ConsultingNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accounting" } } }, "localname": "AccountingExpenses", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "CIK0001818674_BSTPartnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "B S T Partners [Member]" } } }, "localname": "BSTPartnersMember", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/NotesPayableRelatedPartyDetails", "http://sybleuinc.com/role/NotesPayableRelatedPartyDetailsNarrative", "http://sybleuinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CIK0001818674_CommonStockIssuedForPaymentOfExpenses": { "auth_ref": [], "calculation": { "http://sybleuinc.com/role/StatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "CommonStockIssuedForPaymentOfExpenses", "negatedLabel": "Common Stock Issued for payment of expenses" } } }, "localname": "CommonStockIssuedForPaymentOfExpenses", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CIK0001818674_ConsultingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting:" } } }, "localname": "ConsultingAbstract", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "CIK0001818674_ConsultingNet": { "auth_ref": [], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "ConsultingNet", "totalLabel": "Total Consulting" } } }, "localname": "ConsultingNet", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "CIK0001818674_DavidRKoosMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "David R Koos [Member]" } } }, "localname": "DavidRKoosMember", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/NotesPayableRelatedPartyDetails", "http://sybleuinc.com/role/NotesPayableRelatedPartyDetailsNarrative", "http://sybleuinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CIK0001818674_DisclosureStockTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Transactions" } } }, "localname": "DisclosureStockTransactionsAbstract", "nsuri": "http://sybleuinc.com/20210630", "xbrltype": "stringItemType" }, "CIK0001818674_DrJasonGarberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dr Jason Garber [Member]" } } }, "localname": "DrJasonGarberMember", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/StockTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CIK0001818674_DrStephenHakeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dr Stephen Hake [Member]" } } }, "localname": "DrStephenHakeMember", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/StockTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CIK0001818674_EnterpriseValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Enterprise Value as of July 8, 2020" } } }, "localname": "EnterpriseValue", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "monetaryItemType" }, "CIK0001818674_IncreaseDecreaseInSecuritiesAcceptedAsPayment": { "auth_ref": [], "calculation": { "http://sybleuinc.com/role/StatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "(Increase) Decrease in Securities accepted as\u00a0\u00a0Payment" } } }, "localname": "IncreaseDecreaseInSecuritiesAcceptedAsPayment", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CIK0001818674_InvestmentSecuritiesBasis": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Investment Securities, Basis" } } }, "localname": "InvestmentSecuritiesBasis", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/InvestmentSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "CIK0001818674_InvestmentSecuritiesTotalUnrealizedLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Investment Securities, Total Unrealized Losses" } } }, "localname": "InvestmentSecuritiesTotalUnrealizedLosses", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/InvestmentSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "CIK0001818674_LicenseFees": { "auth_ref": [], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "License Fees" } } }, "localname": "LicenseFees", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "CIK0001818674_NumberOfSharesIssuedForPropertyDividend": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of shares issued for property dividend" } } }, "localname": "NumberOfSharesIssuedForPropertyDividend", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/InvestmentSecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "CIK0001818674_OncologyPharmaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Oncology Pharma Inc [Member]" } } }, "localname": "OncologyPharmaIncMember", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/InvestmentSecuritiesDetails", "http://sybleuinc.com/role/InvestmentSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "CIK0001818674_PatentApplicationCosts": { "auth_ref": [], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Patent Application Costs" } } }, "localname": "PatentApplicationCosts", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "CIK0001818674_PerSharePortionOfEnterpriseValueAvailableToCommonShareholders": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Per Share Portion of Enterprise Value available to Common Shareholders" } } }, "localname": "PerSharePortionOfEnterpriseValueAvailableToCommonShareholders", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "perShareItemType" }, "CIK0001818674_PortionOfEnterpriseValueAvailableToCommonShareholders": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Portion of Enterprise Value available to Common Shareholders" } } }, "localname": "PortionOfEnterpriseValueAvailableToCommonShareholders", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "monetaryItemType" }, "CIK0001818674_ScheduleOfCommonSharesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Common Shares" } } }, "localname": "ScheduleOfCommonSharesTableTextBlock", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/InvestmentSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "CIK0001818674_ScheduleOfIssuanceOfStockForNonemployeeServices": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Issuance Of Stock For Non employee Services" } } }, "localname": "ScheduleOfIssuanceOfStockForNonemployeeServices", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "CIK0001818674_ScheduleOfValuationMethodOfFairValueOfUnvestedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Valuation Method Of Fair Value Of Unvested Shares" } } }, "localname": "ScheduleOfValuationMethodOfFairValueOfUnvestedShares", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "CIK0001818674_SharesIssuedVestedDuringPeriodForNonEmployeeServices": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued vested" } } }, "localname": "SharesIssuedVestedDuringPeriodForNonEmployeeServices", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "CIK0001818674_StephenHakeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stephen Hake [Member]" } } }, "localname": "StephenHakeMember", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/GoingConcernDetailsNarrative", "http://sybleuinc.com/role/StockTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CIK0001818674_StockIssuedDuringPeriodSharesIssuedForNonEmployeeServices": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ending balnce, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForNonEmployeeServices", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "CIK0001818674_StockTransactionsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCK TRANSACTIONS" } } }, "localname": "StockTransactionsTextBlock", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/StockTransactions" ], "xbrltype": "textBlockItemType" }, "CIK0001818674_TotalSharesIssuedForNonEmployeeServices": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Shares Issued For Non Employee Services" } } }, "localname": "TotalSharesIssuedForNonEmployeeServices", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "CIK0001818674_TransferAgencyFees": { "auth_ref": [], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Transfer Agency Fees" } } }, "localname": "TransferAgencyFees", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "CIK0001818674_UnvestedSharesForNonEmployeeServices": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unvested Shares at beginning" } } }, "localname": "UnvestedSharesForNonEmployeeServices", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "CIK0001818674_VestedSharesForNonEmployeeServices": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vested Shares" } } }, "localname": "VestedSharesForNonEmployeeServices", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "CIK0001818674_WebsiteDevelopment": { "auth_ref": [], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": 4.0, "parentTag": "CIK0001818674_ConsultingNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Website Development" } } }, "localname": "WebsiteDevelopment", "nsuri": "http://sybleuinc.com/20210630", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r312", "r314", "r315" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/InvestmentSecuritiesDetails", "http://sybleuinc.com/role/InvestmentSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Series [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/InvestmentSecuritiesDetails", "http://sybleuinc.com/role/InvestmentSecuritiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sybleuinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]" } } }, "localname": "DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sybleuinc.com/role/GoingConcernDetailsNarrative", "http://sybleuinc.com/role/NotesPayableRelatedPartyDetails", "http://sybleuinc.com/role/NotesPayableRelatedPartyDetailsNarrative", "http://sybleuinc.com/role/StockTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://sybleuinc.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Expenses Accrued but Unpaid" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r15", "r180", "r248" ], "calculation": { "http://sybleuinc.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r65", "r66", "r67", "r176", "r177", "r178", "r222" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfShareholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net Income (loss) to net cash" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r60", "r100", "r103", "r109", "r118", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r212", "r216", "r226", "r246", "r248", "r268", "r275" ], "calculation": { "http://sybleuinc.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r9", "r28", "r60", "r118", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r212", "r216", "r226", "r246", "r248" ], "calculation": { "http://sybleuinc.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Investment Securities, Fair Value" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/InvestmentSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "BASIS OF ACCOUNTING" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r20", "r248", "r293", "r294" ], "calculation": { "http://sybleuinc.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r20", "r55" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash at End of Period", "periodStartLabel": "Cash at Beginning of Period" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r10", "r56" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "CASH EQUIVALENTS" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r49", "r230" ], "calculation": { "http://sybleuinc.com/role/StatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net Increase (Decrease) in Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r65", "r66", "r222" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfShareholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockOtherSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.", "label": "Common stock, shares outstanding", "verboseLabel": "Common Stock shares outstanding" } } }, "localname": "CommonStockOtherSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheetsParenthetical", "http://sybleuinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value", "verboseLabel": "Common Stock par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheetsParenthetical", "http://sybleuinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized", "verboseLabel": "Common Stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheetsParenthetical", "http://sybleuinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued", "verboseLabel": "Common Stock shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheetsParenthetical", "http://sybleuinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14", "r248" ], "calculation": { "http://sybleuinc.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock ($.0001 par value) 100,000,000 shares authorized; par value $0.0001\u00a0\u00a09,353,000 shares issued and outstanding as of June 30,2020 and 10,418,000 shares issued and outstanding as of June 30,2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r38" ], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Total Costs and Expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COSTS AND EXPENSES" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Debt, Current", "negatedLabel": "Less: Total Debt" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r58", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "NOTES PAYABLE RELATED PARTY" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/NotesPayableRelatedParty" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent": { "auth_ref": [], "calculation": { "http://sybleuinc.com/role/IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed within one year or normal operating cycle, if longer.", "label": "Other" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r189" ], "calculation": { "http://sybleuinc.com/role/IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Asset", "totalLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/IncomeTaxesDetails", "http://sybleuinc.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r191" ], "calculation": { "http://sybleuinc.com/role/IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r195", "r196" ], "calculation": { "http://sybleuinc.com/role/IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating tax carry forwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r190" ], "calculation": { "http://sybleuinc.com/role/IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "BASIC AND FULLY DILUTED LOSS PER SHARE" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r86", "r87" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "BASIC EARNINGS (LOSS) PER SHARE" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r61", "r185", "r205" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Federal Corporate Rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r32", "r33", "r34", "r65", "r66", "r67", "r71", "r78", "r80", "r88", "r119", "r161", "r162", "r176", "r177", "r178", "r198", "r199", "r222", "r231", "r232", "r233", "r234", "r235", "r236", "r285", "r286", "r287", "r322" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfShareholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r117", "r281" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Investment Securities, Net Unrealized Gain or (Loss) realized" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/InvestmentSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r224", "r225" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "FAIR VALUE OF FINANCIAL INSTRUMENTS" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments": { "auth_ref": [ "r53" ], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any gains (losses) realized during the period from the sale of investments accounted for under the cost method of accounting.", "label": "Unrealized Gain ( Loss) on Investment Securities" } } }, "localname": "GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r40" ], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "totalLabel": "Total General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General and Administrative:" } } }, "localname": "GeneralAndAdministrativeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r36", "r100", "r102", "r105", "r108", "r110", "r266", "r271", "r273", "r282" ], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "NET INCOME ( LOSS) Before taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r61", "r186", "r187", "r193", "r203", "r206", "r208", "r209", "r210" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r62", "r79", "r80", "r99", "r184", "r204", "r207", "r283" ], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for Income Taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r31", "r182", "r183", "r187", "r188", "r192", "r197" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r52" ], "calculation": { "http://sybleuinc.com/role/StatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase ( Decrease)\u00a0\u00a0\u00a0in Notes Payable, Related Parties" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r52" ], "calculation": { "http://sybleuinc.com/role/StatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Tax Payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r52" ], "calculation": { "http://sybleuinc.com/role/StatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending": { "auth_ref": [], "calculation": { "http://sybleuinc.com/role/StatementOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying amount of assets, which may include but are not limited to cash and investments, received as collateral pertaining to securities loaned to a counterparty to the transaction. Includes the change during the period in any unrealized gain or loss on such investments.", "label": "Increase (Decrease) in Collateral Held under Securities Lending", "negatedLabel": "Unrealized Loss ( Gain) in Investment Securities" } } }, "localname": "IncreaseDecreaseInCollateralHeldUnderSecuritiesLending", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in Operating Assets and Liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r52" ], "calculation": { "http://sybleuinc.com/role/StatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "(Increase) Decrease in Prepaid Expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InformationTechnologyAndDataProcessing": { "auth_ref": [ "r42" ], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": 5.0, "parentTag": "CIK0001818674_ConsultingNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expenses incurred in the period for information technology and data processing products and services.", "label": "Information Technology Consulting" } } }, "localname": "InformationTechnologyAndDataProcessing", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r124", "r125" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Fair Value of Intellectual Property as of July 8, 2020" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r47", "r50", "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentHoldingsTextBlock": { "auth_ref": [ "r297", "r298", "r299", "r300", "r301" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investment holdings. This includes the long positions of investments for the entity. It contains investments in affiliated and unaffiliated issuers. The investments include securities and non securities (i.e. commodities and futures contracts).", "label": "INVESTMENT SECURITIES" } } }, "localname": "InvestmentHoldingsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/InvestmentSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_Investments": { "auth_ref": [ "r279" ], "calculation": { "http://sybleuinc.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_OtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investment Securities" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r39" ], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "CIK0001818674_ConsultingNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal Fees" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r23", "r60", "r104", "r118", "r126", "r127", "r128", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r213", "r216", "r217", "r226", "r246", "r247" ], "calculation": { "http://sybleuinc.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r60", "r118", "r226", "r248", "r270", "r278" ], "calculation": { "http://sybleuinc.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r25", "r60", "r118", "r126", "r127", "r128", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r213", "r216", "r217", "r226", "r246", "r247", "r248" ], "calculation": { "http://sybleuinc.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r49" ], "calculation": { "http://sybleuinc.com/role/StatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash provided by (used) in Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r49", "r51", "r54" ], "calculation": { "http://sybleuinc.com/role/StatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash provided by (used) in Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r29", "r30", "r34", "r37", "r54", "r60", "r70", "r74", "r75", "r76", "r77", "r79", "r80", "r84", "r100", "r102", "r105", "r108", "r110", "r118", "r126", "r127", "r128", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r223", "r226", "r272", "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfShareholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r1", "r68", "r69", "r72", "r73", "r81", "r82", "r83", "r115", "r116", "r120", "r121", "r164", "r165", "r166", "r167", "r179", "r200", "r201", "r202", "r221", "r227", "r228", "r229", "r237", "r251", "r252", "r253", "r288", "r289", "r290", "r291", "r292", "r323" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "RECENT ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/RecentAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r12", "r269", "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable as of July 8, 2020" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r21", "r63", "r242" ], "calculation": { "http://sybleuinc.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes Payable, Related Party" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesNoncurrent": { "auth_ref": [ "r26", "r63", "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).", "label": "Notes Payable, Related Parties" } } }, "localname": "NotesPayableRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/NotesPayableRelatedPartyDetails", "http://sybleuinc.com/role/NotesPayableRelatedPartyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r100", "r102", "r105", "r108", "r110" ], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "OPERATING Income( LOSS)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r194" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Net operating loss carry forwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r4", "r64", "r96", "r220" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r11", "r267", "r274" ], "calculation": { "http://sybleuinc.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "totalLabel": "Total Other Assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER ASSETS" } } }, "localname": "OtherAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r41", "r284" ], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": 3.0, "parentTag": "CIK0001818674_ConsultingNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Consulting" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "auth_ref": [ "r40" ], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense classified as other.", "label": "Other General and Administrative Expenses" } } }, "localname": "OtherGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r44" ], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "totalLabel": "TOTAL OTHER INCOME ( EXPENSES)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER INCOME AND EXPENSES" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r6", "r8", "r122", "r123" ], "calculation": { "http://sybleuinc.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r45" ], "calculation": { "http://sybleuinc.com/role/StatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Common Stock issued for Cash" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from sale of common stock" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/GoingConcernDetailsNarrative", "http://sybleuinc.com/role/StockTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r46" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from related debt" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r295", "r296" ], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Consulting Costs" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r29", "r30", "r34", "r48", "r60", "r70", "r79", "r80", "r100", "r102", "r105", "r108", "r110", "r118", "r126", "r127", "r128", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r211", "r214", "r215", "r218", "r219", "r223", "r226", "r273" ], "calculation": { "http://sybleuinc.com/role/StatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://sybleuinc.com/role/StatementOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss)", "totalLabel": "NET INCOME ( LOSS)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows", "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r168", "r240", "r241" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/GoingConcernDetailsNarrative", "http://sybleuinc.com/role/NotesPayableRelatedPartyDetails", "http://sybleuinc.com/role/NotesPayableRelatedPartyDetailsNarrative", "http://sybleuinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://sybleuinc.com/role/StockTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r168", "r240", "r243", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/GoingConcernDetailsNarrative", "http://sybleuinc.com/role/NotesPayableRelatedPartyDetails", "http://sybleuinc.com/role/NotesPayableRelatedPartyDetailsNarrative", "http://sybleuinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://sybleuinc.com/role/StockTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r238", "r239", "r241", "r244", "r245" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RentalIncomeNonoperating": { "auth_ref": [ "r43" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income earned by providing the use of assets to an outside party in exchange for a payment or series of payments that is nonoperating in nature.", "label": "Rent" } } }, "localname": "RentalIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r181", "r249", "r302" ], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "totalLabel": "Total Research and Development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development:" } } }, "localname": "ResearchAndDevelopmentExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "RESEARCH AND DEVELOPMENT COSTS" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r162", "r180", "r248", "r277", "r288", "r292" ], "calculation": { "http://sybleuinc.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Deficit )" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r65", "r66", "r67", "r71", "r78", "r80", "r119", "r176", "r177", "r178", "r198", "r199", "r222", "r285", "r287" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfShareholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r35", "r60", "r97", "r98", "r101", "r106", "r107", "r111", "r112", "r113", "r118", "r126", "r127", "r128", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r226", "r273" ], "calculation": { "http://sybleuinc.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "TOTAL REVENUES" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "REVENUES" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of related party debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/NotesPayableRelatedPartyTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r169", "r170", "r171", "r172", "r173" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/GoingConcernDetailsNarrative", "http://sybleuinc.com/role/NotesPayableRelatedPartyDetails", "http://sybleuinc.com/role/NotesPayableRelatedPartyDetailsNarrative", "http://sybleuinc.com/role/StockTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Investments [Abstract]" } } }, "localname": "ScheduleOfInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Investments [Line Items]" } } }, "localname": "ScheduleOfInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/InvestmentSecuritiesDetails", "http://sybleuinc.com/role/InvestmentSecuritiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsTable": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.", "label": "Schedule of Investments [Table]" } } }, "localname": "ScheduleOfInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/InvestmentSecuritiesDetails", "http://sybleuinc.com/role/InvestmentSecuritiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r174", "r175" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "STOCK BASED COMPENSATION" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance at ending, shares", "periodStartLabel": "Balance at beginning, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfShareholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r27", "r32", "r33", "r34", "r65", "r66", "r67", "r71", "r78", "r80", "r88", "r119", "r161", "r162", "r176", "r177", "r178", "r198", "r199", "r222", "r231", "r232", "r233", "r234", "r235", "r236", "r285", "r286", "r287", "r322" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfShareholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfShareholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r65", "r66", "r67", "r88", "r250" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfShareholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfShareholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r13", "r14", "r161", "r162" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfShareholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Common shares issued toParent June 13,2020, share" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfShareholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Common shares issued for non employee services July 8,2020" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfShareholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r13", "r14", "r161", "r162" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Common Shares issued for cash\u00a0\u00a0 November 9,2020" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfShareholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Common shares issued to Parent June 13,2020", "verboseLabel": "Common stock issued" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfShareholdersEquityDeficit", "http://sybleuinc.com/role/StockTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r17", "r18", "r60", "r114", "r118", "r226", "r248" ], "calculation": { "http://sybleuinc.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total Stockholders' Equity (Deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets", "http://sybleuinc.com/role/StatementOfShareholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r59", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r162", "r163" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://sybleuinc.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Income Taxes Payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r89", "r90", "r91", "r92", "r93", "r94", "r95" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "USE OF ESTIMATES" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sybleuinc.com/role/StatementOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r163": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r245": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611322-123010" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r303": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r304": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r305": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r306": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r307": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r308": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r309": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r310": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r311": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r312": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r313": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r314": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r315": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r316": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r317": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r318": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r319": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r320": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r321": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.6)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r64": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693" }, "r83": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" } }, "version": "2.1" } ZIP 51 0001607062-21-000341-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001607062-21-000341-xbrl.zip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